Methods of reducing respiratory system infections

By blocking IL-33ox activity, the activity of rod cells in the airway epithelium of COPD patients is enhanced, which solves the problem of high frequency of respiratory tract infections in COPD patients and achieves the effect of reducing infection and acute exacerbation events.

CN118974084APending Publication Date: 2024-11-15MEDIMMUNE LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380029536.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-25
Filing Date
2023-03-24
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

Patients with chronic obstructive pulmonary disease (COPD) are prone to respiratory infections, especially viral infections, which can lead to acute exacerbations. Current technology lacks effective methods to prevent or reduce these infections.

Method used

Blocking the activity of oxidized IL-33 (IL-33ox) with IL-33 antagonists enhances the activity of rod cells in the airway epithelium, thereby improving the body's defense against infection.

Benefits of technology

By enhancing rod-shaped cell activity, the frequency of respiratory infections and acute exacerbations in COPD patients can be reduced, thus improving their quality of life.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118974084A_ABST
    Figure CN118974084A_ABST
Patent Text Reader

Abstract

The present disclosure relates to methods for reducing infection, particularly respiratory virus infection, in a subject, for example with COPD. The methods comprise the use of an IL-33 antagonist, in particular an oxIL-33 antagonist.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims the benefit under 35 USC §119(e) of U.S. Provisional Patent Application No. 63 / 323,742, filed on March 25, 2022, which is incorporated herein by reference in its entirety for all purposes.

[0003] Reference to a sequence listing submitted electronically

[0004] This application incorporates by reference a sequence listing in computer readable form (CRF) filed as a text file with this application, which sequence listing is named "IL33-207-US-PSP-SequenceListing", created on February 17, 2023, and is 19,729 bytes in size. Technical Field

[0005] The present disclosure relates to methods for reducing or preventing infections, particularly respiratory tract viral infections (RTVI), in subjects with IL-33 mediated respiratory disorders (eg, subjects with COPD). Background Art

[0006] Exacerbations of chronic obstructive pulmonary disease (COPD) are a source of significant distress for patients and a leading cause of morbidity, mortality and hospitalization. Respiratory infections, particularly viral infections, appear to be associated with approximately half of all COPD exacerbations. Only a quarter of exacerbations appear to be unrelated to infection.

[0007] Prevention of COPD exacerbations is an important component of COPD management. Therefore, strategies to prevent infections that lead to exacerbations are needed. They may have a significant impact on COPD morbidity and improve the quality of life of subjects with COPD. Summary of the invention

[0008] Subjects with COPD are particularly susceptible to airway infections that lead to acute exacerbations of COPD. Club cells are an important secretory cell type of the respiratory epithelium with a variety of cellular defense functions. Inhibition of club cell activity has been directly implicated in the increased susceptibility of the airway epithelium to infections such as respiratory syncytial virus (RSV) infection. RSV infection is one of the multiple respiratory viral infections (RTVI) known to cause acute exacerbations of COPD (AECOPD) (Wedzicha, Proc Am Thorac Soc [American Thoracic Society Journal] Vol. 1, pp. 115-120, 2004). The present disclosure relates to the following findings: an oxidized form of IL-33 (IL-33ox) weakens club cell activity in COPD epithelium. These examples show that blocking IL-33ox activity directly repairs club cell activity in COPD air-liquid interface (ALI) cultures. Thus, the present disclosure demonstrates that blocking oxIL-33 activity in subjects with COPD can enhance rod cell activity to reduce infections that lead to acute exacerbations of COPD. Such an approach in a clinical setting could have a significant impact on the incidence of COPD and improve quality of life.

[0009] Thus, in one aspect, the present disclosure provides an IL-33 antagonist for use in a method of reducing or preventing a respiratory infection in a subject with an IL-33-mediated respiratory disorder. In some cases, the IL-33-mediated respiratory disorder is chronic obstructive pulmonary disease (COPD). In some cases, the infection is a respiratory viral infection or a respiratory bacterial infection.

[0010] In some cases, the infection is a respiratory viral infection (RTVI). In some cases, the respiratory viral infection is a respiratory viral infection caused by influenza virus (e.g., influenza A virus, influenza B virus), respiratory syncytial virus (RSV), adenovirus, metapneumovirus, cytomegalovirus, parainfluenza virus (e.g., hPIV-1, hPIV-2, hPIV-3, hPIV-4), rhinovirus, adenovirus, coxsackievirus, echovirus, coronavirus, herpes simplex virus, SARS coronavirus or smallpox.

[0011] In some instances, the IL-33 antagonist inhibits IL-33ox activity, thereby increasing club cell activity in the airway epithelium.

[0012] In some instances, the IL-33 antagonist inhibits IL-33ox activity, thereby increasing total club cell area in the airway epithelium.

[0013] In some cases, the IL-33 antagonist inhibits oxIL-33 activity, thereby increasing the mRNA expression level of one or more markers selected from the following in the airway epithelium: SCGB1BA1, BPIFA1, SCGB3A1, WFDC2, MSMB, LTF, SLPI, C3, HLA-DRA, CXCL1, CD74, CXCL17, MDK, TGM2, HLA-DRB1, CXCL8, CXCL2, HLA-DRB5, CX3CL1 and HLA-DPA1. In some cases, the one or more markers are selected from: SCGB1BA1, BPIFA1, SCGB3A1, WFDC2, MSMB and LTF. In some cases, the one or more markers include SCGB1BA1 and / or BPIFA1.

[0014] In some cases, the IL-33 antagonist inhibits oxIL-33 activity, thereby increasing the protein expression level of one or more markers selected from the following in the airway epithelium: CCSP, SCGB3A1, WFDC2, β-microspermogen, lactoferrin, SPLUNC1, secretory leukocyte protease inhibitor (SLPI), complement C3, HLA-DR α chain, CXC motif chemokine ligand 1 (CXCL1), cluster of differentiation 74 (CD74), CXC motif chemokine 17 (CXCL17), midkine (MDK), protein-glutamate γ-glutamyltransferase 2 (TGM2), HLA class II histocompatibility antigen, DRB1 β chain (HLA-DRB1), chemokine (CXC motif) ligand 8 (CXCL8), chemokine (CXC motif) ligand 2 (CXCL2), HLA Class II histocompatibility antigen, DRB5 beta chain (HLA-DRB5), chemokine (C-X3-C motif) ligand 1 (CX3CL1) and class II major histocompatibility complex, DPα1 (HLA-DPA1). In some cases, the one or more markers are selected from: CCSP, SCGB3A1, WFDC2, β-microspermogenin, lactoferrin and SPLUNC1. In some cases, the one or more markers include CCSP and / or SPLUNC1.

[0015] In some cases, the airway epithelium comprises lower airway epithelium, such as cuboidal epithelium or squamous epithelium. In some cases, the airway epithelium comprises upper airway epithelium, such as ciliated pseudostratified columnar epithelium.

[0016] In some cases, the IL-33 antagonist inhibits IL-33ox activity, thereby increasing the club cell defense function in the airway epithelium. In some cases, increasing the club cell defense function in the airway epithelium comprises increasing the activity of one or more proteins selected from the group consisting of CCSP, SCGB3A1, WFDC2, β-microspermogen, lactoferrin, SPLUNC1, SLPI, C3, HLA-DRA, CXCL1, CD74, CXCL17, MDK, TGM2, HLA-DRB1, CXCL8, CXCL2, HLA-DRB5, CX3CL1, and HLA-DPA1. These proteins have been implicated in epithelial defense function. Therefore, increasing their expression by inhibiting oxIL-33 activity may improve resistance to respiratory infections.

[0017] In some cases, the method reduces the subject's annualized exacerbation rate. In some cases, the method reduces the frequency of acute exacerbations of COPD (AECOPD) in the subject.

[0018] In some instances, the IL-33 antagonist is an IL-33ox antagonist.

[0019] In some cases, the antagonist is an antibody or an antigen-binding fragment thereof. In some cases, the antibody or antigen-binding fragment thereof specifically binds to the reduced form of IL-33 (redIL-33).

[0020] In some instances, the anti-IL-33 antibody or antigen-binding fragment thereof comprises a VH domain comprising a HCDR1 having the sequence shown in SEQ ID NO: 1; a HCDR2 having the sequence shown in SEQ ID NO: 2; and a HCDR3 having the sequence shown in SEQ ID NO: 3; and a VL domain comprising a LCDR1 having the sequence shown in SEQ ID NO: 5; a LCDR2 having the sequence shown in SEQ ID NO: 6, and a LCDR3 having the sequence shown in SEQ ID NO: 7. In some instances, the anti-IL-33 antibody is tozorakimab.

[0021] In another aspect, the disclosure provides a composition comprising an IL-33 antagonist disclosed herein for use in a method of treatment disclosed herein.

[0022] In another aspect, the disclosure provides a method of treating a subject suffering from an IL-33-mediated respiratory disorder to reduce or prevent respiratory infection, comprising administering to the subject a therapeutically effective amount of an IL-33 antagonist.

[0023] In another aspect, the present disclosure provides the use of an IL-33 antagonist for the preparation of a medicament for the treatment of reducing or preventing respiratory infection in a subject suffering from an IL-33-mediated respiratory disorder.

[0024] In another aspect, the present disclosure provides an IL-33 antagonist for use in reducing AECOPD in a subject suffering from COPD, wherein the IL-33 antagonist inhibits IL-33ox activity, thereby reducing respiratory tract infection and AECOPD in the subject. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] Figure 1 Schematic diagram of ALI culture and endpoint assay

[0026] Figure 2 Volcano plot showing the use of IL-33 ox Differential expression of genes by bulk RNA sequencing in treated ALI cultures versus untreated controls

[0027] Figure 3 Compared with untreated controls, IL-33 ox Visual representation of changes in cell type proportions in ALI cultures after treatment

[0028] Figure 4 Heat map showing the use of IL-33 ox Scaled normalized mean expression levels of genes related to mucin production or defense in the secretory state in treated ALI cultures or untreated controls

[0029] Figure 5 Representative immunohistochemistry of COPD ALI cultures after treatment with IL-33 neutralizing antibody (torezumab) or hIgG1 isotype control antibody. MUC5AC / AB (yellow) of goblet cells, acetylated α-tubulin (cyan) of ciliated cells, and p63 (purple) of basal cells (scale bar = 70 μm)

[0030] Figure 6 Flow cytometric analysis of intracellular MUC5AC to quantify the proportion of MUC5AC single-positive goblet cells in dissociated healthy or COPD ALI cultures treated with torelizumab, ST2 neutralizing antibody, or relevant isotype control antibody or in untreated controls (n=6 healthy subjects, n=5 COPD subjects)

[0031] Figure 7 ELISA of MUC5AC secreted into the apical zone of healthy or COPD ALI cultures incubated with torelizumab, ST2 neutralizing antibody, or relevant isotype control or untreated controls (n=7 healthy subjects, n=6 COPD subjects)

[0032] Figure 8 Volcano plot showing differential gene expression from bulk RNA sequencing in COPD ALI cultures treated with IL-33 neutralizing antibody (torezumab)

[0033] Fig. 9 Heat map showing changes in gene expression levels by gene family in COPD ALI cultures after treatment with hIgG1 isotype control antibody or torelizumab

[0034] Fig. 10A Heat map showing the scaled normalized mean expression levels of genes related to mucin production or defense in the secretory state in COPD ALI cultures treated with torelizumab (MEDI3506) or untreated controls

[0035] Fig. 10B Heatmap showing scaled normalized mean expression levels of additional genes associated with defense in the secretory state in COPD ALI cultures treated with torelizumab (MEDI3506) or untreated controls DETAILED DESCRIPTION

[0036] General Definition

[0037] As used herein, "abnormal" refers to a difference in function compared to the function in a healthy subject, typically the function is increased or decreased compared to the function in a healthy subject.

[0038] As used herein, "abnormality of epithelial physiology" refers to any abnormality in the function of an epithelium in the human body. The functions of the epithelium in the human body include: acting as a barrier to protect the underlying tissue; regulation and exchange of chemical entities between tissues and cavities; secretion of chemicals into the cavity; and sensation. Abnormalities in any of these functions may have devastating physiological effects. Epithelium is present in a variety of tissues of the body, including the skin, respiratory tract, gastrointestinal tract, reproductive tract, urinary tract, exocrine glands, and endocrine glands, and therefore, abnormalities within the epithelium may be involved in a variety of diseases or conditions. In some cases, the epithelium is airway epithelium, and the abnormality of epithelial physiology is abnormality of airway epithelial physiology.

[0039] "Antibody" is used in the broadest sense and covers various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, multispecific antibodies (eg, bispecific antibodies), and antibody fragments, so long as they exhibit the desired antigen-binding activity.

[0040] "Antigen-binding fragment" and "binding fragment" refer to molecules other than intact antibodies that contain a portion of an intact antibody that binds to an antigen to which the intact antibody binds. Examples of antibody fragments include, but are not limited to, Fv, Fab, Fab', F(ab')2, Fab'-SH, diabodies, triabodies, tetrabodies, linear antibodies, single-chain antibody molecules (e.g., scFv), and multispecific antibodies formed from antigen-binding fragments. For a review of certain antibody fragments, see Hudson et al., Nat. Med. 9:129-134 (2003). For a review of scFv fragments, see, for example, Pluckthün, in The Pharmacology of Monoclonal Antibodies, Vol. 113, Rosenburg and Moore, eds. (Springer, New York), pp. 269-315 (1994); see also WO 93 / 16185; and U.S. Pat. Nos. 5,571,894 and 5,587,458. For a discussion of Fab fragments and F(ab')2 fragments comprising salvage receptor binding epitope residues and having increased in vivo half-life, see U.S. Pat. No. 5,869,046. Diabodies are antibody fragments having two antigen binding sites that can be bivalent or bispecific. See, e.g., EP 404,097; WO 1993 / 01161; Hudson et al., Nat. Med. [Nature Medicine] 9:129-134 (2003); and Hollinger et al., Proc. Natl. Acad. Sci. USA [Proceedings of the National Academy of Sciences of the United States of America] 90:6444-6448 (1993). Triabodies and tetrabodies are also described in Hudson et al., Nat. Med. 9:129-134 (2003). Single-domain antibodies are antibody fragments that contain all or part of the heavy chain variable domain or all or part of the light chain variable domain of an antibody. Antibody fragments can be prepared by a variety of techniques, including but not limited to proteolytic digestion of intact antibodies and production by recombinant host cells (eg, E. coli or bacteriophage).

[0041] "Rod cells", also known as bronchiolar exocrine cells, formerly known as Clara cells, are low columnar / cuboidal cells with short microvilli, mainly found in the small airways (bronchioles) of the lungs. Rod cells are found in ciliated monolayer epithelia. One of the main functions of rod cells is to protect the bronchiolar epithelium, for example, they protect the bronchiolar epithelium by secreting rod cell secretory protein (CCSP, also known as uteroglobin, CC10 or CC16: UniProtKB accession number P11684). CCSP has a putative anti-inflammatory function and is closely related to regulating the inflammatory response to infection. Wang et al. demonstrated that CCSP-deficient mice infected with RSV increased viral persistence, lung inflammation and airway responsiveness (Wang et al., The Journal of Immunology, 2003, 171: 1051-1060). Therefore, increasing CCSP expression in the small airways can reduce or prevent viral infections such as RSV infection. CCSP is encoded by the gene SCGB1A1.

[0042] As used herein, "IL-33" protein refers to interleukin 33, in particular mammalian interleukin 33 protein, such as the human protein deposited under UniProt No. 095760. IL-33 is not a single substance, but exists in a reduced form and an oxidized form. The reduced form of IL-33 undergoes rapid oxidation in vivo, for example within a time range of 5 minutes to 40 minutes. The terms "IL-33" and "IL-33 polypeptide" are used interchangeably. In some cases, IL-33 is full-length. In another case, IL-33 is mature, truncated IL-33 (amino acids 112 to 270). Recent studies have shown that full-length IL-33 is active (Cayrol and Girard, Proc Natl Acad Sci USA 106(22):9021-6 (2009); Hayakawa et al., Biochem Biophys Res Commun. 387(1):218-22 (2009); Talabot-Ayer et al., J Biol Chem. 284(29):19420-6 (2009)). However, N-terminally processed or truncated IL-33 (including but not limited to aa 72-270, 79-270, 95-270, 99-270, 107-270, 109-270, 111-270, 112-270) may have enhanced activity (Lefrancais 2012, 2014).

[0043] As used herein, "oxidized IL-33", "oxIL-33" or "IL-33ox" refers to a form of IL-33 that binds to RAGE and triggers RAGE-EGFR-mediated signaling. It has been previously shown that activation of the IL-33ox-RAGE / EGFR pathway drives pathogenic changes in lung epithelial components (as disclosed in WO2021 / 089563, which is incorporated herein by reference in its entirety). Oxidized IL-33 refers to a protein that is visible as a distinct band, for example by Western blot analysis under non-reducing conditions, particularly a protein that is 4 Da less in mass than the corresponding reduced form. In particular, it refers to a protein having one or two disulfide bonds between cysteines independently selected from cysteine ​​208, 227, 232 and 259.

[0044] The "Ox-IL-33 / RAGE / EGFR signaling axis" or "oxIL-33 signaling pathway" refers to the RAGE / EGFR signaling pathway that is activated by the binding of oxIL-33 to the RAGE / EGFR signaling complex on the surface of epithelial cells.

[0045] As used herein, "reduced IL-33", "redIL-33" or "IL-33red" refers to a form of IL-33 that binds to ST2 and triggers ST2-mediated signaling. Specifically, cysteine ​​208, 227, 232 and 259 in the reduced form are not disulfide bonded.

[0046] Reference to "WT IL-33" or "IL-33" may refer to the reduced form or the oxidized form, or both, unless it is clear from the context in which these forms are used that one of these forms is intended.

[0047] "IL-33 antagonists" refer to molecules that inhibit the interaction of an IL-33 axis binding partner with one or more of its binding partners. The IL-33 antagonist can be an IL-33red antagonist, an IL-33ox antagonist, or an antagonist that simultaneously inhibits both IL-33red and IL-33ox. The present disclosure also contemplates the use of "oxIL-33 signaling axis antagonists," which, in addition to IL-33ox antagonists, also include RAGE and EGFR antagonists, which complex with IL-33ox to mediate oxIL-33 signaling. Therefore, antagonizing the activity of RAGE and / or EGFR may also be beneficial in inhibiting the pathological oxIL-33 signaling mechanism disclosed herein.

[0048] "IL-33 mediated disorder" refers to a disease or disorder in which IL-33 has been shown to have a pathological role. In particular for the present disclosure, IL-33 mediated respiratory disorders are contemplated. These disorders may also be referred to as IL-33 mediated respiratory disorders. Particular circumstances relate to IL-33 mediated respiratory disorders characterized by abnormalities in epithelial physiology. Such disorders include COPD, asthma, COPD overlap syndrome (ACOS), chronic bronchitis, bronchiectasis, and emphysema.

[0049] "Aggravation of COPD" or "COPD aggravation" refers to the increase in severity and / or frequency and / or duration of one or more symptoms or indicators of COPD. "Aggravation of COPD" also includes any deterioration of the respiratory health of the subject that requires therapeutic intervention (such as steroid treatment, antibiotic treatment, inhaled corticosteroid treatment, hospitalization, etc.) and / or can be treated by the therapeutic intervention. In some cases, moderate aggravation is defined as an acute exacerbation of COPD (AECOPD) event that requires systemic corticosteroids (such as intramuscular, intravenous or oral) and / or antibiotic treatment. In some cases, severe aggravation is defined as an AECOPD event that requires hospitalization, emergency medical treatment or causes death. In some cases, the annualized rate of moderate to severe acute exacerbation of COPD (AECOPD) includes moderate aggravation and severe aggravation.

[0050] "Reduction in the frequency of exacerbations of COPD" means that a subject who has received an IL-33 antagonist as disclosed herein experiences fewer COPD exacerbations after treatment than before treatment (ie, at least one less exacerbation), or has not experienced a COPD exacerbation for at least 4 weeks (e.g., 4, 6, 8, 12, 14 or more weeks) after starting treatment with an IL-33 antagonist disclosed herein.

[0051] "Reducing infection" or "preventing infection" means that a subject who has received an IL-33 antagonist as disclosed herein experiences fewer infections (ie, at least one less infection) after treatment than before treatment, or has not experienced an infection for at least 4 weeks (eg, 4, 6, 8, 12, 14 or more weeks) after starting treatment with an IL-33 antagonist disclosed herein. Given that more than 50% of COPD exacerbations are caused by infections (eg, respiratory viral infections), a reduction in COPD exacerbations can be an effective indicator for determining a reduction in infection rates. If infections are reduced, the number of exacerbations is expected to decrease at the same time.

[0052] An "effective amount" or "therapeutically effective amount" of an agent (eg, a pharmaceutical formulation) refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic or prophylactic result.

[0053] The term "subject" refers to an animal, human or non-human, to which treatment is provided according to the methods of the present invention. Veterinary and non-veterinary applications are contemplated. The term includes, but is not limited to, mammals, such as humans, other primates, pigs, rodents (such as mice and rats), rabbits, guinea pigs, hamsters, cattle, horses, cats, dogs, sheep and goats. Typical subjects include humans, farm animals and domestic pets (such as cats and dogs). Preferred subjects are humans.

[0054] Treatment

[0055] The present disclosure provides methods for reducing or preventing infections, particularly respiratory infections (such as respiratory viral infections or respiratory bacterial infections). These methods are particularly useful for subjects with IL-33-mediated respiratory disorders, particularly subjects with abnormal epithelial physiology. Abnormal epithelial physiology can be characterized by an imbalance in the cell types that normally make up the respiratory epithelium.

[0056] The present disclosure provides evidence that an oxidized form of IL-33 (IL-33ox) inhibits club cell activity in the airway epithelium. Club cells are a type of secretory epithelial cell that have multiple cellular defense functions. Inhibition of IL-33ox activity restores club cell activity in the epithelium, including increasing expression of club cell-related genes with defense functions. This may improve the epithelium's defense against infections (such as viral or bacterial infections), which lead to exacerbations of diseases such as COPD.

[0057] Thus, in some cases, the disclosure provides an IL-33 antagonist for use, a method of treatment comprising administering the IL-33 antagonist, and the use of the IL-33 antagonist in the manufacture of a medicament for reducing or preventing respiratory infections in subjects with IL-33-mediated respiratory disorders. It should be understood that for each instance disclosing an "IL-33 antagonist for use", a corresponding "method of treatment" or "use" of the IL-33 antagonist is contemplated.

[0058] In some cases, the IL-33-mediated respiratory disorder is selected from asthma, chronic obstructive pulmonary disease (COPD), asthma-COPD overlap syndrome (ACOS), chronic bronchitis or emphysema. In some cases, the IL-33-mediated disorder is COPD. These disorders can exhibit abnormalities in epithelial physiology, in which rod cell activity may be reduced. For example, these examples show that air-liquid interface (ALI) cultures of COPD epithelium exhibit reduced total rod cell area and reduced mRNA and protein expression levels of rod cell markers compared to healthy control ALI. The examples demonstrate that this dysfunction is at least partially mediated by IL-33ox. After treatment with an IL-33 antagonist that inhibits IL-33ox activity, total rod cell area and rod cell marker mRNA and protein expression levels are restored. Therefore, the examples show that IL-33 antagonists can be used to restore rod cell activity in the airway epithelium of subjects suffering from IL-33-mediated respiratory disorders such as COPD.

[0059] In some cases, the epithelium is selected from the group consisting of squamous, cuboidal, columnar, and pseudostratified epithelium. In some cases, the epithelium is ciliated pseudostratified columnar epithelium. In some cases, the epithelium is cuboidal epithelium. In some cases, the epithelium is squamous epithelium.

[0060] In some cases, the IL-33-mediated respiratory disorder is COPD. COPD is a chronic inflammatory lung disease that causes airflow obstruction in the lungs. Multiple lines of evidence suggest that IL-33 is a driver of the chronic inflammation observed in the lungs of COPD subjects. Several ongoing clinical trials using IL-33 antagonists attempt to limit the chronic inflammation observed in COPD subjects. However, it is not known to date that IL-33 directly affects rod cell function in the epithelium. Therefore, the present disclosure establishes for the first time that IL-33 antagonists can be used to directly affect airway epithelial physiology to increase rod cell function, thereby improving defenses against respiratory infections.

[0061] In some cases, a subject is identified as having COPD if the subject receives a diagnosis of "mild," "moderate," "severe," or "very severe" COPD from a physician based on the Global Initiative for Chronic Obstructive Lung Disease (GOLD) (Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2017 Report) (Available at: goldcopd.org / wp-content / uploads / 2016 / 12 / wms-GOLD-2017-Pocket-Guide.pdf.)). In these cases, the subject's COPD is classified based on the severity of airway limitation as measured by the FEV1 test after the use of a bronchodilator. If the subject's FEV1 is greater than or equal to 25% to 80% of the predicted FEV1, the subject's COPD is classified as "mild" using the GOLD classification system. The predicted value for FEV1 is based on the FEV1 value of an average person of similar age, race, height, and sex who has healthy lungs. If the subject's FEV1 is greater than or equal to 50% of the predicted FEV1 but less than 80% of the predicted FEV1, the subject's COPD is classified as "moderate" based on the GOLD classification system. If the subject's FEV1 is greater than or equal to 30% of the predicted FEV1 but less than 50% of the predicted FEV1, the subject's COPD is classified as "severe" based on the GOLD classification system. If the subject's FEV1 is less than 30% of the predicted FEV1, the subject's COPD is classified as "very severe" based on the GOLD classification system.

[0062] In some cases, IL-33 antagonists are used to prevent or reduce respiratory tract infections. As used herein, "respiratory infection," "respiratory tract infection," and "RTI" have the same meaning. RTI is an infection of a part of the body involved in breathing, such as the sinuses, throat, airways, or lungs.

[0063] In some cases, IL-33 antagonists are used to reduce or prevent respiratory infections in the lungs (also referred to herein as "pulmonary respiratory infections").

[0064] In some cases, IL-33 antagonists are used to reduce or prevent respiratory infections in the airways (also referred to herein as "airway respiratory infections").

[0065] In some cases, IL-33 antagonists are used to reduce or prevent respiratory infections in the small airways (also referred to herein as "small airway respiratory infections").

[0066] Club cells are primarily located in the bronchioles of the lung, and thus the IL-33 antagonists disclosed herein may be particularly beneficial in reducing infections that arise in areas where club cells are primarily located.

[0067] In some cases, IL-33 antagonists can be used to reduce or prevent infections caused by viruses (also known as "respiratory viral infections," "respiratory tract viral infections," or "RTVI").

[0068] In some cases, the IL-33 antagonist can be used to reduce or prevent RTVI caused by influenza virus (e.g., influenza A virus, influenza B virus), respiratory syncytial virus (RSV), adenovirus, metapneumovirus, cytomegalovirus, parainfluenza virus (e.g., hPIV-1, hPIV-2, hPIV-3, hPIV-4), rhinovirus, adenovirus, coxsackievirus, echovirus, coronavirus, herpes simplex virus, SARS coronavirus, or smallpox.

[0069] In some cases, IL-33 antagonists can be used to reduce infections caused by bacteria (also known as "respiratory bacterial infections" or "respiratory bacterial infections"). In some cases, IL-33 antagonists can be used to reduce infections caused by Chlamydia pneumoniae or Mycoplasma pneumoniae.

[0070] In some cases, reducing or preventing infection includes increasing the total rod cell area in the respiratory epithelium. In some cases, the IL-33 antagonist inhibits or reduces IL-33ox activity, thereby increasing the total rod cell area in the respiratory epithelium. In some cases, the respiratory epithelium is upper airway epithelium. In some cases, the upper airway epithelium is ciliated pseudostratified columnar epithelium. In some cases, the epithelium is lower airway epithelium. In some cases, the lower airway epithelium is cuboidal epithelium. In some cases, the lower airway epithelium is squamous epithelium.

[0071] These examples demonstrate that blocking IL-33ox activity increases the proportion of club cells in COPD ALI cultures, thereby restoring the total area of ​​club cells similar to that seen in healthy controls. Restoring club cell area increases the expression of club cell defense genes. Therefore, increasing club cell area and club cell defense function may reduce or prevent infection in subjects with IL-33-mediated disorders who are previously susceptible to RTVI.

[0072] Total rod cell area can be measured by measuring markers from relevant biological samples obtained from the subject. In some cases, the biological sample can be a biopsy, for example, a respiratory epithelial biopsy, bronchial brushings, bronchoalveolar fluid (BALF), sputum, serum, plasma, or nasal mucosal lining fluid. In some cases, the biological sample is obtained from respiratory epithelium. If an increase in marker concentration is detected in the subject after treatment, this indicates that the treatment has successfully increased the total rod cell area in the respiratory epithelium.

[0073] In some cases, the marker may be the mRNA expression level of SCGB1A1. In some cases, the marker may be the mRNA expression level of SCGB3A1. In some cases, the marker may be the mRNA expression level of WFDC2. In some cases, the marker may be the mRNA expression level of MSMB. In some cases, the marker may be the mRNA expression level of BPIFA1. In some cases, the mRNA expression level of one or more of SCGB1A1, SCGB3A1, WFDC2, MSMB, and BPIFA1 increases after treatment compared to a reference mRNA expression level of one or both markers, indicating that total rod cell area has increased.

[0074] In some cases, the marker may be the protein expression level of CCSP. In some cases, the marker may be the protein expression level of SPLUNC1. In some cases, the marker may be the protein expression level of secretoglobin family 3A member 1 (SCGB3A1). In some cases, the marker may be the protein expression level of WAP four-disulfide core domain protein 2 (WFDC2). In some cases, the marker may be the protein expression level of β-microspermogenin. In some cases, the protein expression level of one or more of CCSP, SCGB3A1, WFDC2, β-microspermogenin, lactoferrin, and SPLUNC1 increases after treatment compared to the protein reference expression level of one or both markers, indicating that the total rod cell area has increased.

[0075] In some cases, the reference expression level is the level determined in a biological sample obtained from a subject prior to treatment with an IL-33 antagonist. In some cases, mRNA expression levels are measured by qRT-PCR. In some cases, protein expression levels are measured by enzyme-linked immunosorbent assay (ELISA), immunohistochemistry (IHC), immunofluorescence, flow cytometry, or Western blotting.

[0076] In some cases, reducing or preventing infection includes increasing the mRNA expression level of SCGB1A1. In some cases, the IL-33 antagonist inhibits or reduces IL-33ox activity, thereby increasing the mRNA expression level of SCGB1A1. In some cases, the increased mRNA expression level is in the epithelium. In some cases, the increased expression is in the airway epithelium. In some cases, the increased expression is in the upper airway epithelium. In some cases, the increased expression is in the ciliated pseudostratified columnar epithelium. In some cases, the increased expression is in the lower airway epithelium. In some cases, the increased expression is in the small airway epithelium. In some cases, the increased mRNA expression level is in the cuboidal epithelium. In some cases, the increased mRNA expression level is in the squamous epithelium. SCGB1A1 encodes CCSP, which, as described elsewhere herein, is secreted by club cells and has been shown to regulate lung inflammation and immune responses to RSV infection (Wang et al., The Journal of Immunology, 2003, 171: 1051-1060). These examples demonstrate that treatment with an IL-33 antagonist increases the expression of SCGB1A1 from COPD epithelium, thereby increasing anti-inflammatory and immune response activity to agents that cause infection. In some cases, the increased expression is in club 1 cells, club 2 cells, club 3 cells, or club 4 cells.

[0077] Suitable samples and methods of measuring and determining increased mRNA expression levels of SCGB1A1 are disclosed elsewhere herein.

[0078] In some cases, reducing or preventing infection includes increasing the protein expression level of CCSP. In some cases, IL-33 antagonists inhibit or reduce IL-33ox activity, thereby increasing the protein expression level of CCSP. In some cases, the increased protein expression level is in the epithelium. In some cases, the increased expression is in the airway epithelium. In some cases, the increased protein expression level is in the upper airway epithelium. In some cases, the increased protein expression level is in the ciliated pseudostratified columnar epithelium. In some cases, the increased protein expression level is in the lower airway epithelium. In some cases, the increased protein expression level is in the small airway epithelium. In some cases, the increased protein expression level is in the cuboidal epithelium. In some cases, the increased protein expression level is in the squamous epithelium.

[0079] Suitable samples and methods of measuring and determining increased protein expression levels of CCSP are disclosed elsewhere herein.

[0080] In some cases, reducing or preventing infection includes increasing CCSP activity. In some cases, IL-33 antagonists inhibit or reduce IL-33ox activity, thereby increasing CCSP activity. In some cases, the increased CCSP activity is in the epithelium. In some cases, the increased CCSP activity is in the airway epithelium. In some cases, the increased CCSP activity is in the upper airway epithelium. In some cases, the increased CCSP activity is in the ciliated pseudostratified columnar epithelium. In some cases, the increased CCSP activity is in the lower airway epithelium. In some cases, the increased CCSP activity is in the small airway epithelium. In some cases, the increased CCSP activity is in the cuboidal epithelium. In some cases, the increased CCSP activity is in the squamous epithelium.

[0081] In some cases, reducing or preventing infection includes increasing the mRNA expression level of BPIFA1. In some cases, IL-33 antagonists inhibit or reduce IL-33ox activity, thereby increasing the mRNA expression level of BPIFA1. In some cases, the increased mRNA expression level is in the epithelium. In some cases, the increased expression is in the airway epithelium. In some cases, the increased expression is in the upper airway epithelium. In some cases, the increased expression is in the ciliated pseudostratified columnar epithelium. In some cases, the increased expression is in the lower airway epithelium. In some cases, the increased expression is in the small airway epithelium. In some cases, the increased mRNA expression level is in the cuboidal epithelium. In some cases, the increased mRNA expression level is in the squamous epithelium. BPIFA1 encodes a family A member 1 (BPIFA1, also known as SPLUNC1) containing the BPI fold, which has been shown to play a role in the innate immune response of the upper airway. Sayyed et al. showed that BPIFIA1 protects the host from Pseudomonas aeruginosa bacterial infection in the upper respiratory tract (Sayeed et al., Infect. Immun. 81:285-291 (2013)). In some cases, the increased expression is in rod 1 cells, rod 2 cells, rod 3 cells, or rod 4 cells.

[0082] Suitable samples and methods of measuring and determining increased mRNA expression levels of BPFIA are disclosed elsewhere herein.

[0083] In some cases, reducing or preventing infection includes increasing the protein expression level of SPLUNC1. In some cases, IL-33 antagonists inhibit or reduce IL-33ox activity, thereby increasing the protein expression level of SPLUNC1. In some cases, the increased protein expression level is in the epithelium. In some cases, the increased expression is in the airway epithelium. In some cases, the increased protein expression level is in the upper airway epithelium. In some cases, the increased protein expression level is in the ciliated pseudostratified columnar epithelium. In some cases, the increased protein expression level is in the lower airway epithelium. In some cases, the increased protein expression level is in the small airway epithelium. In some cases, the increased protein expression level is in the cuboidal epithelium. In some cases, the increased protein expression level is in the squamous epithelium.

[0084] Suitable samples and methods of measuring and determining increased protein expression levels of SPLUNC1 are disclosed elsewhere herein.

[0085] In some cases, reducing or preventing infection includes increasing SPLUNC1 activity. In some cases, IL-33 antagonists inhibit or reduce IL-33ox activity, thereby increasing SPLUNC1 activity. In some cases, the increased SPLUNC1 activity is in the epithelium. In some cases, the increased SPLUNC1 activity is in the airway epithelium. In some cases, the increased SPLUNC1 activity is in the upper airway epithelium. In some cases, the increased SPLUNC1 activity is in the ciliated pseudostratified columnar epithelium. In some cases, the increased SPLUNC1 activity is in the lower airway epithelium. In some cases, the increased SPLUNC1 activity is in the small airway epithelium. In some cases, the increased SPLUNC1 activity is in the cubic epithelium. In some cases, the increased SPLUNC1 activity is in the squamous epithelium.

[0086] In some cases, reducing or preventing infection includes increasing the mRNA expression level of SCGB3A1. In some cases, the IL-33 antagonist inhibits or reduces IL-33ox activity, thereby increasing the mRNA expression level of SCGB3A1. In some cases, the increased mRNA expression level is in the epithelium. In some cases, the increased expression is in the airway epithelium. In some cases, the increased expression is in the upper airway epithelium. In some cases, the increased expression is in the ciliated pseudostratified columnar epithelium. In some cases, the increased expression is in the lower airway epithelium. In some cases, the increased expression is in the small airway epithelium. In some cases, the increased expression is in the cuboidal epithelium. In some cases, the increased expression is in the squamous epithelium. SCGB3A1 encodes SCGB3A1, a cytokine-like protein secreted by club cells that has been shown to inhibit cell growth in vitro (Krop et al., PNAS [Proceedings of the National Academy of Sciences of the United States of America], 2001, 98:9796-9801; Zuo et al., Am J Respir Crit Care Med [American Journal of Respiratory and Critical Care Medicine], 2018, 198:1375-1388). These examples show that treatment with an IL-33 antagonist increases the expression of SCGB3A1 from COPD epithelium. In some cases, the increased expression is in club 1 cells, club 2 cells, club 3 cells, or club 4 cells. In some cases, the increased expression is in club 1, club 2, or club 3 cells.

[0087] Suitable samples and methods of measuring and determining increased mRNA expression levels of SCGB3A1 are disclosed elsewhere herein.

[0088] In some cases, reducing or preventing infection includes increasing the protein expression level of SCGB3A1. In some cases, the IL-33 antagonist inhibits or reduces IL-33ox activity, thereby increasing the protein expression level of SCGB3A1. In some cases, the increased protein expression level is in the epithelium. In some cases, the increased expression is in the airway epithelium. In some cases, the increased protein expression level is in the upper airway epithelium. In some cases, the increased protein expression level is in the ciliated pseudostratified columnar epithelium. In some cases, the increased protein expression level is in the lower airway epithelium. In some cases, the increased protein expression level is in the small airway epithelium. In some cases, the increased protein expression level is in the cuboidal epithelium. In some cases, the increased protein expression level is in the squamous epithelium.

[0089] Suitable samples and methods of measuring and determining increased protein expression levels of SCGB3A1 are disclosed elsewhere herein.

[0090] In some cases, reducing or preventing infection includes increasing SCGB3A1 activity. In some cases, IL-33 antagonists inhibit or reduce IL-33ox activity, thereby increasing SCGB3A1 activity. In some cases, the increased SCGB3A1 activity is in the epithelium. In some cases, the increased SCGB3A1 activity is in the airway epithelium. In some cases, the increased SCGB3A1 activity is in the upper airway epithelium. In some cases, the increased SCGB3A1 activity is in the ciliated pseudostratified columnar epithelium. In some cases, the increased SCGB3A1 activity is in the lower airway epithelium. In some cases, the increased SCGB3A1 activity is in the small airway epithelium. In some cases, the increased SCGB3A1 activity is in the cuboidal epithelium. In some cases, the increased SCGB3A1 activity is in the squamous epithelium.

[0091] In some cases, reducing or preventing infection includes increasing the mRNA expression level of WFDC2. In some cases, IL-33 antagonists inhibit or reduce IL-33ox activity, thereby increasing the mRNA expression level of WFDC2. In some cases, the increased mRNA expression level is in the epithelium. In some cases, the increased expression is in the airway epithelium. In some cases, the increased expression is in the upper airway epithelium. In some cases, the increased expression is in the ciliated pseudostratified columnar epithelium. In some cases, the increased expression is in the lower airway epithelium. In some cases, the increased expression is in the small airway epithelium. In some cases, the increased mRNA expression level is in the cubic epithelium. In some cases, the increased mRNA expression level is in the squamous epithelium. WFDC2 encodes WAP tetra-disulfide core domain 2 (WFDC2), an antiprotease with host cell defense function expressed by rod cells (Zuo et al., Am J Respir Crit Care Med, 2018, 198: 1375-1388). These examples show that treatment with an IL-33 antagonist increases the expression of WFDC2 from COPD epithelium. In some cases, the increased expression is in rod 1 cells, rod 2 cells, rod 3 cells, or rod 4 cells. In some cases, the increased expression is in rod 3 or rod 4 cells.

[0092] Suitable samples and methods of measuring and determining increased mRNA expression levels of WFDC2 are disclosed elsewhere herein.

[0093] In some cases, reducing or preventing infection includes increasing the protein expression level of WFDC2. In some cases, IL-33 antagonists inhibit or reduce IL-33ox activity, thereby increasing the protein expression level of WFDC2. In some cases, the increased protein expression level is in the epithelium. In some cases, the increased expression is in the airway epithelium. In some cases, the increased protein expression level is in the upper airway epithelium. In some cases, the increased protein expression level is in the ciliated pseudostratified columnar epithelium. In some cases, the increased protein expression level is in the lower airway epithelium. In some cases, the increased protein expression level is in the small airway epithelium. In some cases, the increased protein expression level is in the cuboidal epithelium. In some cases, the increased protein expression level is in the squamous epithelium.

[0094] Suitable samples and methods of measuring and determining increased protein expression levels of WFDC2 are disclosed elsewhere herein.

[0095] In some cases, reducing or preventing infection includes increasing WFDC2 activity. In some cases, IL-33 antagonists inhibit or reduce IL-33ox activity, thereby increasing WFDC2 activity. In some cases, the increased WFDC2 activity is in the epithelium. In some cases, the increased WFDC2 activity is in the airway epithelium. In some cases, the increased WFDC2 activity is in the upper airway epithelium. In some cases, the increased WFDC2 activity is in the ciliated pseudostratified columnar epithelium. In some cases, the increased WFDC2 activity is in the lower airway epithelium. In some cases, the increased WFDC2 activity is in the small airway epithelium. In some cases, the increased WFDC2 activity is in the cubic epithelium. In some cases, the increased WFDC2 activity is in the squamous epithelium.

[0096] In some cases, reducing or preventing infection includes increasing the mRNA expression level of MSMB. In some cases, IL-33 antagonists inhibit or reduce IL-33ox activity, thereby increasing the mRNA expression level of MSMB. In some cases, the increased mRNA expression level is in the epithelium. In some cases, the increased expression is in the airway epithelium. In some cases, the increased expression is in the upper airway epithelium. In some cases, the increased expression is in the ciliated pseudostratified columnar epithelium. In some cases, the increased expression is in the lower airway epithelium. In some cases, the increased expression is in the small airway epithelium. In some cases, the increased mRNA expression level is in the cuboidal epithelium. In some cases, the increased mRNA expression level is in the squamous epithelium. MSMB encodes β-microspermogen secreted by rod cells (Zuo et al., Am J RespirCrit Care Med [American Journal of Respiratory and Critical Care Medicine], 2018, 198: 1375-1388). These examples demonstrate that treatment with an IL-33 antagonist increases the expression of β-microspermogen from COPD epithelium. In some cases, the increased expression is in club 1 cells, club 2 cells, club 3 cells, or club 4 cells. In some cases, the increased expression is in club 1, club 2, or club 3 cells.

[0097] Suitable samples and methods of measuring and determining increased mRNA expression levels of MSMB are disclosed elsewhere herein.

[0098] In some cases, reducing or preventing infection includes increasing the protein expression level of β-microsperm. In some cases, IL-33 antagonists inhibit or reduce IL-33ox activity, thereby increasing the protein expression level of β-microsperm. In some cases, the increased protein expression level is in the epithelium. In some cases, the increased expression is in the airway epithelium. In some cases, the increased protein expression level is in the upper airway epithelium. In some cases, the increased protein expression level is in the ciliated pseudostratified columnar epithelium. In some cases, the increased protein expression level is in the lower airway epithelium. In some cases, the increased protein expression level is in the small airway epithelium. In some cases, the increased protein expression level is in the cuboidal epithelium. In some cases, the increased protein expression level is in the squamous epithelium.

[0099] Suitable samples and methods of measuring and determining increased protein expression levels of β-microspermogenin are disclosed elsewhere herein.

[0100] In some cases, reducing or preventing infection includes increasing β-spermogen activity. In some cases, IL-33 antagonists inhibit or reduce IL-33ox activity, thereby increasing β-spermogen activity. In some cases, the increased β-spermogen activity is in the epithelium. In some cases, the increased β-spermogen activity is in the airway epithelium. In some cases, the increased β-spermogen activity is in the upper airway epithelium. In some cases, the increased β-spermogen activity is in the ciliated pseudostratified columnar epithelium. In some cases, the increased β-spermogen activity is in the lower airway epithelium. In some cases, the increased β-spermogen activity is in the small airway epithelium. In some cases, the increased β-spermogen activity is in the cuboidal epithelium. In some cases, the increased β-spermogen activity is in the squamous epithelium.

[0101] In some cases, reducing or preventing infection includes increasing the mRNA expression level of LTF. In some cases, an IL-33 antagonist inhibits or reduces IL-33ox activity, thereby increasing the mRNA expression level of LTF. In some cases, the increased mRNA expression level is in the epithelium. In some cases, the increased expression is in the airway epithelium. In some cases, the increased expression is in the upper airway epithelium. In some cases, the increased expression is in the ciliated pseudostratified columnar epithelium. In some cases, the increased expression is in the lower airway epithelium. In some cases, the increased expression is in the small airway epithelium. In some cases, the increased mRNA expression level is in the cuboidal epithelium. In some cases, the increased mRNA expression level is in the squamous epithelium. LTF encodes lactotransferrin, an antimicrobial protein with multiple host cell defense functions. It is known to be expressed in airway epithelia, such as submucosal secretory glands and surface epithelia (Dubin et al., Am J Physiol Lung Cell Mol Physiol [American Journal of Physiology - Lung Cell and Molecular Physiology] 286: L750-L755, 2004). These examples show that treatment with IL-33 antagonists increases the expression of LTF in COPD epithelium. In some cases, the increased expression is in rod 1 cells, rod 2 cells, rod 3 cells, or rod 4 cells. In some cases, the increased expression is in rod 4 cells.

[0102] Suitable samples and methods of measuring and determining increased mRNA expression levels of LTF are disclosed elsewhere herein.

[0103] In some cases, reducing or preventing infection includes increasing the protein expression level of lactotransferrin. In some cases, IL-33 antagonists inhibit or reduce IL-33ox activity, thereby increasing the protein expression level of lactotransferrin. In some cases, the increased protein expression level is in the epithelium. In some cases, the increased expression is in the airway epithelium. In some cases, the increased protein expression level is in the upper airway epithelium. In some cases, the increased protein expression level is in the ciliated pseudostratified columnar epithelium. In some cases, the increased protein expression level is in the lower airway epithelium. In some cases, the increased protein expression level is in the small airway epithelium. In some cases, the increased protein expression level is in the cuboidal epithelium. In some cases, the increased protein expression level is in the squamous epithelium.

[0104] Suitable samples and methods of measuring and determining increased protein expression levels of lactotransferrin are disclosed elsewhere herein.

[0105] In some cases, reducing or preventing infection includes increasing lactoferrin activity. In some cases, IL-33 antagonists inhibit or reduce IL-33ox activity, thereby increasing lactoferrin activity in respiratory epithelia. In some cases, the increased lactoferrin activity is in the epithelium. In some cases, the increased lactoferrin activity is in the airway epithelium. In some cases, the increased lactoferrin activity is in the upper airway epithelium. In some cases, the increased lactoferrin activity is in the ciliated pseudostratified columnar epithelium. In some cases, the increased lactoferrin activity is in the lower airway epithelium. In some cases, the increased lactoferrin activity is in the small airway epithelium. In some cases, the increased lactoferrin activity is in the cuboidal epithelium. In some cases, the increased lactoferrin activity is in the squamous epithelium.

[0106] In some cases, IL-33 antagonists reduce or prevent infection by increasing the rod cell defense function in the airway epithelium. In some cases, increasing the rod cell defense function includes increasing the mRNA expression level of one or more rod cell defense genes. In some cases, one or more rod cell defense genes are selected from the following: SCGB1BA1, BPIFA1, SCGB3A1, WFDC2, MSMB, LTF, SLPI, C3, HLA-DRA, CXCL1, CD74, CXCL17, MDK, TGM2, HLA-DRB1, CXCL8, CXCL2, HLA-DRB5, CX3CL1 and HLA-DPA1. In some cases, one or more rod cell defense genes are selected from: SCGB1BA1, BPIFA1, SCGB3A1, WFDC2, MSMB and LTF. In some cases, one or more rod cell defense genes are SCGB1BA1 and BPIFA1. In some cases, increasing the club cell defense function comprises increasing the protein expression level of one or more proteins with club cell defense function selected from the group consisting of CCSP, SCGB3A1, WFDC2, β-microspermogenin, lactoferrin, SPLUNC1, SLPI, C3, HLA-DRA, CXCL1, CD74, CXCL17, MDK, TGM2, HLA-DRB1, CXCL8, CXCL2, HLA-DRB5, CX3CL1, and HLA-DPA1. In some cases, the one or more proteins with club cell defense function are selected from the group consisting of CCSP, SCGB3A1, WFDC2, β-microspermogenin, lactoferrin, and SPLUNC1. In some cases, the one or more proteins with club cell defense function are CCSP and SPLUNC1. In some cases, the club cell defense genes include SCGB1A1, LTF, and / or BPIFA1.

[0107] In some cases, reducing or preventing infection comprises increasing the mRNA expression level of one or more markers selected from the group consisting of SLPI, C3, HLA-DRA, CXCL1, CD74, CXCL17, MDK, TGM2, HLA-DRB1, CXCL8, CXCL2, HLA-DRB5, CX3CL1, and HLA-DPA1.

[0108] In some instances, reducing or preventing infection comprises increasing the protein expression level of one or more of the following markers: secretory leukocyte protease inhibitor (SLPI), complement C3, HLA-DR alpha chain, CXC motif chemokine ligand 1 (CXCL1), cluster of differentiation 74 (CD74), CXC motif chemokine 17 (CXCL17), midkine (MDK), protein-glutamate amine gamma-glutamyltransferase 2 (TGM2), HLA class II histocompatibility antigen, DRB1 beta chain (HLA-DRB1), chemokine (CXC motif) ligand 8 (CXCL8), chemokine (CXC motif) ligand 2 (CXCL2), HLA class II histocompatibility antigen, DRB5 beta chain (HLA-DRB5), chemokine (C-X3-C motif) ligand 1 (CX3CL1), and class II major histocompatibility complex, DP alpha 1 (HLA-DPA1).

[0109] In some instances, reducing or preventing infection comprises increasing the activity of one or more of: SLPI, C3, HLA-DRA, CXCL1, CD74, CXCL17, MDK, TGM2, HLA-DRB1, CXCL8, CXCL2, HLA-DRB5, CX3CL1, and HLA-DPAl.

[0110] In some cases, reducing or preventing infection comprises increasing the mRNA expression level of one or more markers selected from the list consisting of: SLPI, C3, HLA-DRA, CXCL1, CD74, CXCL17, MDK, TGM2, HLA-DRB1, CXCL8, CXCL2, HLA-DRB5, CX3CL1, and HLA-DPA1.

[0111] In some cases, reducing or preventing infection comprises increasing the protein expression level of one or more markers selected from the list consisting of SLPI, C3, HLA-DRA, CXCL1, CD74, CXCL17, MDK, TGM2, HLA-DRB1, CXCL8, CXCL2, HLA-DRB5, CX3CL1, and HLA-DPA1.

[0112] In some cases, reducing or preventing infection comprises increasing the activity of one or more markers selected from the list consisting of SLPI, C3, HLA-DRA, CXCL1, CD74, CXCL17, MDK, TGM2, HLA-DRB1, CXCL8, CXCL2, HLA-DRB5, CX3CL1, and HLA-DPA1.

[0113] In some cases, reducing or preventing infections reduces the annualized exacerbation rate of COPD. More than 50% of exacerbations are caused by respiratory viral infections. Therefore, improving rod cell activity and thereby reducing the frequency of RTVI in subjects with COPD may reduce the annualized exacerbation rate of subjects.

[0114] Reducing or preventing infections will reduce the frequency of acute exacerbations of COPD (AECOPD) in the following circumstances:

[0115] On the other hand, the present disclosure provides an IL-33 antagonist for use in a method for preventing or reducing the treatment of respiratory infections in subjects with COPD. This is achieved by increasing the activity of rod cells in the airway epithelium by inhibiting the activity of IL-33ox. The respiratory tract infection can be any infection described elsewhere herein. In certain cases, the respiratory tract infection can be a respiratory viral infection. The reduction in respiratory tract infection can be determined by monitoring the frequency of acute exacerbations of COPD (AECOPD) in the subject. If the number of AECOPD in the subject for a period of time after treatment is statistically lower than the number of AECOPD in the same period of time before treatment, it indicates that the treatment has reduced the respiratory tract infection in the subject. This is because in COPD, more than 50% of AECOPD are caused by respiratory infections.

[0116] In some cases, the period of time is greater than 6 months. In some cases, the period of time is greater than 12 months. In some cases, the period of time is 12 to 24 months. In some cases, the period of time is 18 months, 20 months, 22 or 24 months. In some cases, the period of time is 24 months.

[0117] In another aspect, the disclosure provides an IL-33 antagonist for use in a method of reducing the treatment of AECOPD in a subject with COPD, wherein the IL-33 antagonist attenuates or inhibits IL-33ox activity, thereby reducing respiratory tract infection in the subject.

[0118] In some cases, attenuation or inhibition of IL-33ox activity increases club cell defense function, thereby reducing respiratory tract infection in a subject.

[0119] In some cases, attenuation or inhibition of IL-33ox activity increases club cell defenses, thereby reducing respiratory infections in subjects.

[0120] In some cases, attenuation or inhibition of IL-33ox activity increases the mRNA expression level of one or more of the markers described elsewhere herein, thereby reducing respiratory tract infection in the subject.

[0121] In some cases, attenuation or inhibition of IL-33ox activity increases the protein expression level of one or more of the markers described elsewhere herein, thereby reducing respiratory tract infection in a subject.

[0122] In some cases, attenuation or inhibition of IL-33ox activity increases the activity of one or more proteins having a rod cell defense function described elsewhere herein, thereby reducing respiratory tract infection in a subject.

[0123] In some cases, attenuation or inhibition of IL-33ox activity increases the total rod cell area in the subject's epithelium, thereby reducing respiratory infections in the subject. In some cases, the epithelium is airway epithelium. In some cases, the epithelium is upper airway epithelium. In some cases, the epithelium is ciliated pseudostratified columnar epithelium. In some cases, the epithelium is lower airway epithelium. In some cases, the epithelium is small airway epithelium. In some cases, the epithelium is cuboidal epithelium. In some cases, the epithelium is squamous epithelium.

[0124] IL-33 antagonists

[0125] The methods described herein include the use of IL-33 antagonists.

[0126] In some cases, the IL-33 antagonist is a binding molecule. In some cases, the binding molecule specifically binds to IL33. Such binding molecules are also referred to as "IL-33 binding molecules" or "anti-IL-33 binding molecules". In some cases, the binding molecule specifically binds to IL-33 and inhibits or weakens IL-33 activity.

[0127] In some cases, the IL-33 antagonist is an antibody or an antigen-binding fragment thereof. It is contemplated that antibodies or antigen-binding portions thereof that specifically bind to and inhibit components of the oxIL-33 / RAGE / EGFR signaling axis can be used in the methods disclosed herein.

[0128] In some cases, the binding molecule is an antibody. In some cases, the antibody can be a monoclonal antibody (mAb), a recombinant antibody, a chimeric antibody, a humanized antibody (such as a human antibody with a complementary determining region (CDR) grafted thereto); antibody variants, including single-chain and / or bispecific antibodies, and antigen-binding fragments, variants or derivatives thereof. Antigen-binding fragments include those portions of the antibody that bind to an epitope on a target polypeptide. Examples of such antigen-binding fragments include Fab and F(ab') fragments generated by enzymatic cleavage of a full-length antibody. Other antigen-binding fragments include fragments generated by recombinant DNA technology (such as expressing a recombinant plasmid containing a nucleic acid sequence encoding an antibody variable region).

[0129] As used herein, "monoclonal antibody" or "monoclonal antibody composition" refers to polypeptides having substantially the same amino acid sequence or derived from the same genetic source, including antibodies, bispecific antibodies, etc. The term also includes preparations of antibody molecules of a single molecular composition. A monoclonal antibody composition exhibits a single binding specificity and affinity for a particular epitope.

[0130] A "chimeric" antibody is an antibody in which a portion of the heavy (H) chain and / or light (L) chain is identical or homologous to a corresponding sequence in an antibody derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain is identical or homologous to a corresponding sequence in an antibody derived from another species or belonging to another antibody class or subclass. Fragments of such antibodies are also included as long as they exhibit the desired biological activity. See U.S. Pat. No. 4,816,567; Morrison et al., 1985, Proc. Natl. Acad. Sci. [Proceedings of the National Academy of Sciences of the United States of America] 81:6851-55.

[0131] In one case, the monoclonal antibody is a "humanized" antibody. Methods for humanizing non-human antibodies are well known in the art. See U.S. Patent Nos. 5,585,089 and 5,693,762. Typically, a humanized antibody has one or more amino acid residues introduced therein from a non-human source. Humanization can be performed, for example, using methods described in the art (Jones et al., 1986, Nature [Nature] 321: 522-25; Riechmann et al., 1998, Nature [Nature] 332: 323-27; Verhoeyen et al., 1988, Science [Science] 239: 1534-36), by replacing at least a portion of a rodent complementary determining region with the corresponding region of a human antibody.

[0132] Human antibodies or antigen-binding fragments thereof that bind to IL-33 are also contemplated. Such antibodies are produced by immunizing with a polypeptide antigen (i.e., having at least 6 consecutive amino acids) using transgenic animals (e.g., mice) that are capable of producing a human antibody repertoire in the absence of endogenous immunoglobulin production, optionally conjugated to a carrier. See, e.g., Jakobovits et al., 1993, Proc. Natl. Acad. Sci. [Proceedings of the National Academy of Sciences of the United States] 90:2551-55; Jakobovits et al., 1993, Nature [Nature] 362:255-58; Bruggermann et al., 1993, Year in Immuno. [Year of Immunology] 7:33. See also PCT Application Nos. PCT / US 96 / 05928 and PCT / US 93 / 06926. Additional methods are described in US Pat. No. 5,545,807, PCT Application Nos. PCT / US 91 / 245 and PCT / GB 89 / 01207, and European Patent Nos. 54607381 and 546073A 1. Human antibodies can also be produced by expressing recombinant DNA in host cells or by expression in hybridoma cells as described herein.

[0133] Chimeric antibodies, CDR grafted antibodies, and humanized antibodies and / or antibody variants are typically produced by recombinant methods. Nucleic acids encoding antibodies are introduced into host cells and expressed using materials and procedures described herein. In an example, antibodies are produced in mammalian host cells, such as CHO cells. Monoclonal (e.g., human) antibodies can also be produced by expressing recombinant DNA in host cells or by expressing in hybridoma cells as described herein.

[0134] The antibodies and antigen-binding fragments thereof that can be used in the methods of the present disclosure may comprise: (a) a heavy chain variable region comprising a HCDR1 having a sequence as set forth in SEQ ID NO: 1, a VHCDR2 having a sequence of SEQ ID NO: 2, and a VHCDR3 having a sequence of SEQ ID NO: 3; and (b) a light chain variable region comprising a VLCDR1 having a sequence of SEQ ID NO: 5, a VLCDR2 having a sequence of SEQ ID NO: 6, and a VLCDR3 having a sequence of SEQ ID NO: 7.

[0135] In some instances, the IL-33 antibody or antigen-binding fragment thereof comprises a VH domain comprising VHCDR 1 to VHCDR 3 of SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3, respectively.

[0136] In some instances, the IL-33 antibody or antigen-binding fragment thereof comprises a VH domain comprising VHCDR 1 to VHCDR 3 consisting of SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3, respectively.

[0137] In some instances, the anti-IL-33 antibody or antigen-binding fragment thereof comprises the HCDR1, HCDR2, and HCDR3 sequences of the VH domain having the sequence shown in SEQ ID NO:4.

[0138] In some instances, the IL-33 antibody or antigen-binding fragment thereof comprises a variable heavy chain domain (VH) and a VL having a variable light chain domain (VL) CDR 1 to VL CDR 3, VL CDR 1 to VL CDR 3 having the sequences of SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7, respectively, wherein one or more VLCDRs have 3 or fewer single amino acid substitutions, insertions, and / or deletions.

[0139] In some instances, the IL-33 antibody or antigen-binding fragment thereof comprises a VL domain comprising VLCDR 1 to VHCDR 3 of SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7, respectively.

[0140] In some instances, the IL-33 antibody or antigen-binding fragment thereof comprises a VL domain comprising VLCDR 1 to VHCDR 3 consisting of SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7, respectively.

[0141] In some cases, the anti-IL-33 antibody or antigen-binding fragment thereof comprises a LCDR1, LCDR2, and LCDR3 sequence of a VL domain having the sequence shown in SEQ ID NO:8.

[0142] Also contemplated is an anti-IL-33 antibody or antigen-binding fragment thereof for use in the methods disclosed herein, comprising a heavy chain variable region (VH) domain that is at least 95%, 90%, or 85% identical to the sequence shown in SEQ ID NO: 4. In some cases, the anti-IL-33 antibody or antigen-binding fragment thereof comprises a light chain variable region (VL) domain that is at least 95%, 90%, or 85% identical to the sequence shown in SEQ ID NO: 8. In some cases, the anti-IL-33 antibody or antigen-binding fragment thereof comprises: (a) a heavy chain variable region (VH) that is at least 95%, 90%, or 85% identical to the sequence set forth in SEQ ID NO: 4; and (b) a light chain variable region (VL) that is at least 95%, 90%, or 85% identical to the sequence set forth in SEQ ID NO: 8. In some cases, the anti-IL-33 antibody is 33_640087_7B, as disclosed in WO 2016 / 156440, which is incorporated herein by reference. 33_640087_7B, also known in the art as MEDI3506 or torelizumab, is an anti-IL-33 antibody that binds with high affinity to the reduced form of IL-33 (redIL-33). 33_640087_7B also inhibits the conversion of redIL-33 to the oxidized form (oxIL-33), which has been shown to induce signaling via RAGE and induce epithelial cell proliferation. A Ph3 clinical trial (NCT05166889) investigating the efficacy and safety of torelizumab (MEDI3506) in symptomatic COPD with a history of exacerbations is currently underway.

[0143] 33_640087_7B is an exemplary anti-IL-33 antibody having: (a) a heavy chain variable region comprising a HCDR1 having a sequence as set forth in SEQ ID NO: 1, a VHCDR2 having a sequence of SEQ ID NO: 2, and a VHCDR3 having a sequence of SEQ ID NO: 3; and (b) a light chain variable region comprising a VLCDR1 having a sequence of SEQ ID NO: 5, a VLCDR2 having a sequence of SEQ ID NO: 6, and a VLCDR3 having a sequence of SEQ ID NO: 7.

[0144] 33_640087_7B also comprises a VH domain having the amino acid sequence set forth in SEQ ID NO:4 and a VL domain having the amino acid sequence set forth in SEQ ID NO:8.

[0145] 33_640087_7B is an IgG1 antibody, and the sequences of the full-length light chain and heavy chain (including the IgG1 chain) of 33_640087_7B are listed in SEQ ID NOs: 9 and 10, respectively.

[0146] Other exemplary IL-33 binding antagonists include anti-IL-33 antibodies or antigen-binding fragments thereof, including ANB020, known as Etokimab (described in WO 2015 / 106080), itepekimab, 9675P (described in US2014 / 0271658), A25-3H04 (described in US2017 / 0283494), Ab43 (described in WO 2018 / 081075), IL33-158 (described in US2018 / 0037644), 10C12.38.H6.87Y.581lgG4 (described in WO2016 / 077381), or binding fragments thereof. Other exemplary anti-IL-33 antibodies or antigen-binding fragments thereof include any other anti-IL-33 antibodies described in WO 2016 / 156440, WO 2015 / 106080, US 2014 / 0271658, US 2017 / 0283494, WO 2018 / 081075, US 2018 / 0037644, or WO 2016 / 077381 (all of which are incorporated herein by reference).

[0147] In some cases, the anti-IL-33 antibody or antigen-binding fragment thereof has similar or identical pharmacokinetic (pK) characteristics in humans as 33_670087_7B.

[0148] In some instances, the IL-33 binding molecule specifically binds to the reduced form of IL-33 (IL-33red), the oxidized form of IL-33 (IL-33ox), or both IL-33red and IL-33ox.

[0149] In some cases, the IL-33 binding molecule can attenuate or inhibit IL-33 activity by binding to IL-33 in reduced or oxidized form. In some cases, the binding molecule inhibits or attenuates reduced IL-33 activity and oxidized IL-33 activity by binding to IL-33 in reduced form (i.e., by binding to reduced IL-33). In this case, the binding molecule can bind to IL-33red and prevent its conversion to IL-33ox.

[0150] In some cases, the binding molecule can specifically bind to redIL-33 with a binding affinity (Kd) of less than 5 x 10 -2 M, 10 -2 M, 5x 10 -3 M, 10 -3 M, 5x 10 -4 M, 10 -4M, 5x 10 -5 M, 10 -5 M, 5x 10 -6 M, 10 -6 M, 5x 10 -7 M, 10 -7 M, 5x 10 -8 M, 10 -8 M, 5x 10 -9 M, 10 -9 M, 5x 10 -10 M, 10 -10 M, 5x 10 -11 M, 10 -11 M, 5x 10 -12 M, 10 -12 M, 5x 10 -13 M, 10 -13 M, 5x 10 -14 M, 10 -14 M, 5x 10 -15 M or 10 -15 M. In some cases, the binding affinity to redIL-33 is less than 5 x 10 -14 M (i.e., 0.05 pM). In some cases, binding affinity is measured using kinetic exclusion assay (KinExA) or BIACORE TM In some cases, binding affinity is measured using KinExA, using protocols such as those described in WO 2016 / 156440 (see, e.g., Example 11, which is hereby incorporated by reference in its entirety). It has been found that binding molecules that bind to redIL-33 with this binding affinity bind tightly enough to prevent the binding molecule / redIL-33 complex from dissociating within a biologically relevant time scale. Without wishing to be bound by theory, this binding strength is believed to prevent the release of the antigen prior to the degradation of the binding molecule / antigen complex in vivo, thereby minimizing any IL-33-dependent activity associated with the release of IL-33 from the binding complex.

[0151] In some cases, the binding molecules can be present in an amount greater than or equal to 10 3 M -1 sec -1 , 5X 10 3 M -1 sec -1 , 10 4 M -1 sec -1 or 5X 10 4 M -1 sec -1For example, the binding molecules disclosed herein can bind specifically to redIL-33 at an association rate (k(on)) greater than or equal to 10 5 M -1 sec -1 , 5X 10 5 M -1 sec -1 , 10 6 M -1 sec -1 or 5X 10 6 M -1 sec -1 or 10 7 M -1 sec -1 The association rate (k(on)) of the invention binds to redIL-33 or a fragment or variant thereof. In some cases, the k(on) rate is greater than or equal to 10 7 M -1 sec -1 In some cases, the binding molecules can be present at a concentration of less than or equal to 5×10 -1 sec -1 , 10 -1 sec -1 , 5X 10 - 2 sec -1 , 10 -2 sec -1 、5X10 -3 sec -1 or 10 -3 sec -1 For example, it can be said that the binding molecules of the present disclosure bind specifically to redIL-33 at a dissociation rate (k(off)) of less than or equal to 5×10 -4 sec -1 , 10 -4 sec -1 , 5X 10 -5 sec -1 or 10 - 5 sec -1 , 5X 10 -6 sec -1 , 10 -6 sec -1 , 5X 10 -7 sec -1 or 10 -7 sec -1 The dissociation rate (k(off)) of the redIL-33 or its fragment or variant is less than or equal to 10-3 sec -1 . IL-33 is an alarm cytokine that rapidly releases high concentrations of cytokines in response to inflammatory stimuli. redIL-33 is converted to an oxidized form approximately 5 to 45 minutes after being released into the extracellular environment (Cohen et al., Nat Commun [Natural Communications] 6, 8327 (2015)). Without wishing to be bound by theory, binding to redIL-33 at these k(on) and / or k(off) rates can minimize exposure to redIL-33 before the reduced form is converted to oxIL-33. In addition, the k(off) rate can prevent IL-33 from being released from the binding molecule / antigen complex before the complex is degraded in vivo. These binding kinetics can also play a role in preventing the conversion of redIL-33 to oxIL-33, thereby preventing pathological signaling of the oxidized form of IL-33 via RAGE / EGFR (described in WO 2021 / 089563, which is incorporated herein by reference).

[0152] In some cases, the IL-33 antibody or antigen-binding fragment thereof can competitively inhibit the binding of IL-33 to 33_640087-7B (as described in WO 2016 / 156440). WO 2016 / 156440 discloses that 33_640087-7B binds to redIL-33 with particularly high affinity and attenuates both ST-2 and RAGE-dependent IL-33 signaling. If an antibody or antigen-binding fragment thereof specifically binds to a given epitope to an extent that blocks the binding of a reference antibody to the epitope to some extent, the antibody or antigen-binding fragment thereof is said to competitively inhibit the binding of a reference antibody to the epitope. Competitive inhibition can be determined by any method known in the art, such as a solid phase assay (such as a competitive ELISA assay), a dissociation enhanced lanthanide fluorescence immunoassay ( PerkinElmer) and radioligand binding assays. For example, a technician can determine whether an antibody or an antigen-binding fragment thereof competes for binding to IL-33 by using an in vitro competitive binding assay (such as the HTRF assay described in paragraphs 881 to 886 of WO 2016 / 156440), which is incorporated herein by reference. For example, a technician can label 33_640087-7B with a donor fluorophore and mix multiple concentrations of 33_640087-7B with a fixed concentration of a redIL-33 sample labeled with an acceptor fluorophore. Subsequently, the fluorescence resonance energy transfer between the donor and acceptor fluorophores in each sample can be measured to determine the binding characteristics. In order to illustrate competitive binding antibody molecules, a technician can first mix various concentrations of test binding molecules with a fixed concentration of labeled 33_640087-7B antibodies. When the mixture is incubated with labeled IL-33, a reduction in the FRET signal indicates competitive binding to IL-33 compared to a positive control of labeled antibody alone. An antibody or antigen-binding fragment thereof can be considered to competitively inhibit binding of a reference antibody to a given epitope by at least 90%, at least 80%, at least 70%, at least 60%, or at least 50%.

[0153] In various cases, the anti-IL-33 antibody or antigen-binding fragment thereof is selected from a human antibody, a humanized antibody, a chimeric antibody, a monoclonal antibody, a recombinant antibody, an antigen-binding antibody fragment, a single-chain antibody, a monomeric antibody, a double-chain antibody, a three-chain antibody, a four-chain antibody, a Fab fragment, an IgG1 antibody, an IgG2 antibody, an IgG3 antibody, and an IgG4 antibody. In some cases, the anti-IL-33 antibody or antigen-binding fragment thereof is selected from the group consisting of a double-chain antibody, a three-chain antibody, a four-chain antibody, a Fab fragment, a single domain antibody, and a scFv, wherein the dose is adjusted so that the binding sites are equimolar to those binding sites administered by the bivalent antibody.

[0154] In some cases, the anti-IL-33 antibody or antigen-binding fragment thereof binds to IL-33 comprising the amino acid sequence of SEQ ID NO: 11. In various cases, the anti-IL-33 antibody or antigen-binding fragment thereof may be capable of binding to the mature form of the full-length IL-33 protein comprising the amino acid sequence of SEQ ID NO: 11. In various cases, the anti-IL-33 antibody or antigen-binding fragment thereof may be capable of binding to an IL-33 protein fragment comprising amino acids 72 to 270, 79 to 270, 95 to 270, 99 to 270, 107 to 270, 109 to 270, 111 to 270, or 112 to 270 of SEQ ID NO: 11.

[0155] In many cases, the anti-IL-33 antibody or antigen-binding fragment thereof may be able to bind to reduced (red-IL-33) and / or oxidized (ox-IL-33) forms of IL-33. In some cases, the anti-IL-33 antibody or antibody variant thereof may be able to preferentially bind to reduced (red-IL-33) and / or oxidized (ox-IL-33) forms of IL-33.

[0156] In various cases, the anti-IL-33 antibody or antigen-binding fragment thereof may be an inhibitory antibody capable of inhibiting IL-33 or a fragment thereof as defined herein. In various cases, the inhibitory antibody may be capable of inhibiting the association of IL-33 or a fragment thereof with an IL-33 receptor.

[0157] In some instances, the anti-IL-33 antibody comprises a light chain sequence as set forth in SEQ ID NO:9 and a heavy chain sequence as set forth in SEQ ID NO:10.

[0158] In some instances, the anti-IL-33 antibody comprises a light chain having the sequence shown in SEQ ID NO:9 and a heavy chain having the sequence shown in SEQ ID NO:10.

[0159] In some instances, the anti-IL-33 antibody comprises a light chain consisting of the sequence shown in SEQ ID NO:9 and a heavy chain consisting of the sequence shown in SEQ ID NO:10.

[0160] In some cases, the binding molecule inhibits IL-33ox activity. In some cases, the binding molecule inhibits the binding of IL-33ox to the RAGE / EGFR complex.

[0161] Composition and administration

[0162] The IL-33 antagonists in the medical uses and methods described herein can be administered to a patient in the form of a pharmaceutical composition.

[0163] Suitably, any reference to "a / the IL-33 antagonist" herein may also refer to a pharmaceutical composition comprising an / the IL-33 antagonist. Suitably, the pharmaceutical composition may comprise one or more IL-33 antagonists.

[0164] Suitably, the IL-33 antagonist may be administered in a pharmaceutically effective amount for in vivo treatment as described herein.

[0165] Suitably, the IL-33 antagonist or pharmaceutical composition thereof can be administered to humans or other animals in an amount sufficient to produce a therapeutic effect according to the aforementioned treatment methods / medical uses.

[0166] Suitably, the IL-33 antagonist or its pharmaceutical composition can be administered to such humans or other animals in conventional dosage forms prepared by combining the IL-33 antagonist with conventional pharmaceutically acceptable carriers or diluents according to known techniques.

[0167] Those skilled in the art will recognize that the form and characteristics of the pharmaceutically acceptable carrier or diluent are determined by the amount of active ingredient combined therewith, the route of administration, and other well-known variables. Those skilled in the art will further appreciate that mixtures containing one or more species of IL-33 antagonists may prove to be particularly effective.

[0168] The amount of IL-33 antagonist that can be combined with a carrier material to produce a single dosage form will vary depending on the subject being treated and the particular mode of administration. Suitably, the pharmaceutical composition can be administered as a single dose, multiple doses, or as an infusion over a determined period of time. Suitably, the dosage regimen can also be adjusted to provide the optimal desired response (e.g., a therapeutic or prophylactic response).

[0169] Suitably, the IL-33 antagonist is formulated so as to facilitate administration of the IL-33 antagonist and to enhance its stability.

[0170] Suitably, the pharmaceutical composition is formulated to contain a pharmaceutically acceptable non-toxic sterile carrier, such as physiological saline, non-toxic buffers, preservatives and the like.

[0171] Suitably, the pharmaceutical composition may comprise a pharmaceutically acceptable carrier, a sterile aqueous or non-aqueous solution, suspension and / or emulsion.

[0172] Suitably, pharmaceutical compositions for injectable use may include sterile aqueous solutions (when soluble in water) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In such cases, the composition must be sterile and should have fluidity to the extent of being easily injectable. It should be stable under manufacturing and storage conditions and will be stored to prevent the contaminating effects of microorganisms (such as bacteria and fungi).

[0173] Suitable formulations for use in the methods of treatment disclosed herein are described in Remington's Pharmaceutical Sciences (Mack Publishing Co.), 16th edition (1980).

[0174] Suitably, prevention of microbial action can be achieved by various antibacterial and antifungal agents. In many cases, it will be appropriate to include an isotonic agent in the pharmaceutical composition. Prolonged absorption of the injectable composition can be achieved by including an agent that delays absorption in the composition.

[0175] Suitably, sterile injectable solutions can be prepared by mixing the IL-33 antagonist in the desired amount in an appropriate solvent with one or a combination of ingredients listed herein as required, followed by filtration sterilization. Typically, dispersions are prepared by incorporating the active compound into a sterile vehicle containing a basic dispersion medium and other desired ingredients from those listed above. In the case of sterile powders for the preparation of sterile injectable solutions, the preparation methods may be vacuum drying and freeze drying, which produce a powder of the active ingredient and any other desired ingredients from a previously sterile filtered solution thereof.

[0176] Methods of administering an IL-33 antagonist or a pharmaceutical composition thereof to a subject in need thereof can be readily determined by one skilled in the art.

[0177] Suitably, the route of administration of the IL-33 antagonist or its pharmaceutical composition may be, for example, oral, parenteral, inhaled or topical. Suitably, the term parenteral as used herein includes, for example, intravenous, intraarterial, intraperitoneal, intramuscular, subcutaneous, rectal or vaginal administration.

[0178] Suitably, the IL-33 antagonist or pharmaceutical composition thereof may be administered orally in an acceptable dosage form including, for example, capsules, tablets, aqueous suspensions or solutions.

[0179] Suitably, the parenteral formulation may be a single bolus dose, an infusion or a loading bolus dose, followed by a maintenance dose. These compositions may be administered at specific fixed or variable intervals, for example once daily, or on an "as needed" basis.

[0180] Suitably, the components described above for preparing the pharmaceutical compositions described herein can be packaged and sold in the form of a kit. Such a kit will suitably have a label or package insert indicating that the relevant pharmaceutical composition can be used to treat a subject suffering from or prone to a disease or disorder.

[0181] Examples

[0182] The airway epithelium plays a central role in the development and progression of chronic airway diseases (Carlier et al., Front. Physiol. [Frontiers in Physiology] 12, 691227 (2021)). Continuous exposure to pathogens and noxious stimuli alters the structure and composition of the airway epithelium and may lead to irreversible changes, such as those that occur in chronic airway diseases (Carlier et al., Front. Physiol. [Frontiers in Physiology] [Frontiers in Physiology] 12, 691227 (2021); Hogg et al., Annu. Rev. Pathol. [Annual Review of Pathology] 4, 435-459 (2009)). Genetic analysis suggests that IL-33 drives the pathology of chronic airway diseases such as asthma and COPD: rare loss-of-function mutations in IL-33 reduce the risk of asthma and COPD, while gain-of-function mutations are associated with an increased risk of COPD (Rabe et al., Lancet Respir. Med. 9, 1288-1298 (2021); Smith et al., PLoS Genet. 13, e1006659 (2017)). IL-33 binds to cell surface IL-1 receptor-like 1 (IL1RL1, also known as ST2), activates the NF-κB inflammatory signaling pathway and leads to chronic airway inflammation (Liew et al., Nat. Rev. Immunol. 16, 676-689 (2016)).

[0183] The effects of IL-33 on immune cells are well established. However, recently emerging evidence suggests that IL-33 has direct effects on epithelial cells. In vitro epithelial injury assays and validated IL-33 pathway blockers have demonstrated that oxidized forms of IL-33 (oxIL-33 or IL-33ox) signal through a newly described RAGE / EGFR signaling pathway, which transforms the functional dynamics of the airway epithelium (as disclosed in WO 2021 / 089563, which is incorporated herein by reference).

[0184] In this study, transcriptional dynamics in the airway epithelium were investigated to further elucidate the role of the RAGE / EGFR complex in health and disease.

[0185] IL-33 ox Changing the fate of epithelial cells

[0186] To study IL-33 oxDriven transcriptional changes in the lung epithelium, normal human bronchial epithelial (NHBE) cells from healthy donors were differentiated into air-liquid interface (ALI) cultures, mimicking human epithelial physiology (Zscheppang et al., Biotechnol. J. [Journal of Biotechnology] 13, 1700341 (2018)) ( Figure 1 ).

[0187] Compared with no treatment, IL-33 ox Treatment induced a number of transcriptional changes ( Figure 2 ).

[0188] IL-33 ox The expression of genes associated with epithelial cell differentiation was decreased, and the expression of genes associated with negative regulation of wound closure was increased (data not shown). Genes associated with mitochondrial organization, ATP metabolism, endoplasmic reticulum / Golgi vesicle transport, and cellular stress markers were also upregulated (data not shown).

[0189] Next, we investigated IL-33 at the single-cell level. ox Transcriptional changes induced in ALI cultures derived from healthy donors (Hewitt et al., Nat. Rev. Immunol. [Nature Review Immunology] 21, 347-362 (2021)). We identified 15 cell states in untreated healthy ALI cultures that represent the main airway epithelial cell types and are consistent with the complex cellular heterogeneity observed in vivo (Jackson et al., Cell Rep. [Cell Report] 32, 107872 (2020); Ruiz Garcia et al., Development [Development] 146, dev177428 (2019)) (Table 1). In the presence of IL-33 ox After treatment, the proportion of secretory and basal cells in healthy ALI cultures increased, while the proportion of ciliated cells and rare cell types decreased ( Figure 3 ). In the secretory cell population, IL-33 ox The proportion of mucus-producing cells increased after treatment, while mature club cells (club 3, which participate in epithelial defense and express high levels of SCGB1A1 and SCGB3A1 (Zuo et al., Crit. Care Med. [Intensive Care Medicine] 198, 1375-1388 (2018)) decreased.

[0190] Table 1: Fifteen cell states were identified in healthy ALI cultures, representing the cellular heterogeneity observed in vivo

[0191]

[0192]

[0193] Differential gene expression analysis showed that rod-related genes involved in epithelial defense function (such as SCGB1A1, SCGB3A1, BPIFA1, WFDC2 and MSMB) (Zuo et al., Crit. Care Med. [Critical Care Medicine] 198, 1375-1388 (2018); Akram et al., Mucosal Immunol. [Mucosal Immunology] 11, 71-81 (2018); Goldfarbmuren et al., Nat. Commun. [Nature Communications]. 11, 2485 (2020)) were downregulated in all secretory cells ( Figure 4 ). Notably, the most differentially expressed genes in the single-cell data were consistent with the bulk RNA sequencing data (data not shown). Overall, these data suggest that IL-33 ox Driving epithelial remodeling at the expense of club and ciliated cell status may reduce the intrinsic anti-infective defenses of the epithelium. This phenotype may contribute to the increased risk of respiratory tract infections in subjects with COPD, which is the main cause of COPD exacerbation events.

[0194] Blocking IL-33 reverses key features of COPD

[0195] Chronic exposure to exogenous IL-33 ox The epithelial changes induced are reminiscent of those observed in the airway epithelium of COPD patients (Kesimer et al., N. Engl. J. Med. [New England Journal of Medicine] 377, 911-922 (2017); Ha et al., Pharmacology [Pharmacology] 97, 84-100 (2016); Boucher N. Engl. J. Med [New England Journal of Medicine]. 380, 1941-1953 (2019); Kim et al. Am. J. Respir. Crit. Care Med. [American Journal of Respiratory and Critical Care Medicine] 187, 228-237 (2013)).

[0196] Inhibition of IL-33 with torelizumab in COPD ALI cultures reduced the proportion of mucus-secreting cells and the amount of MUC5AC released ( Figures 5 to 7 These effects were not observed after selective blockade of ST2 (data not shown), suggesting that IL-33 ox may be the driver of this phenotype.

[0197] In addition, IL-33 ox Inhibition of signaling induced substantial transcriptomic changes, restoring genes associated with cilia and club cells, thereby reversing the COPD phenotype in ALI cultures ( Figure 8 and 9 We observed downregulation of genes known to be involved in goblet cell differentiation and carbohydrate biosynthesis, and upregulation of genes associated with detoxification functions, club cells, and ciliary organization and assembly ( Fig. 9 ).

[0198] Using single-cell transcriptomics, we investigated the effects of blocking endogenous IL-33 signaling in COPDALI cultures (Figure 10). Although no major changes in the proportions of different cell states were observed, inhibition of IL-33 signaling upregulated genes associated with epithelial host defense functions and club cell markers such as SCGB1A1 and SCGB3A1 (Mootz et al., Allergy https: / / doi.org / 10.1111 / all.15033, https: / / doi.org / 10.1111 / all.15033(2021)) (Figure 10).

[0199] discuss

[0200] This study reveals a previously unknown mechanism of IL-33 ox We hypothesized that IL-33 may play a role in altering the transcriptional and functional dynamics of airway epithelium through the newly described RAGE / EGFR signaling pathway. ox It plays a protective role in the lung during acute injury or infection, but overexposure during chronic injury disrupts normal repair processes, leading to epithelial dysfunction, mucus hypersecretion, and pathogenesis. Recent clinical data suggest that inhibition of IL-33 in COPD patients has clinical benefits (Rabe et al. Based on our findings, we speculate that targeting inhibition of IL-33 ox and IL-33 red Therapies that target both signaling pathways will be more effective than those that target only IL-33. red "Our results suggest that torelizumab could restore pathogenic properties of the COPD epithelium and restore club cell defense mechanisms, thereby reducing infections that lead to COPD exacerbations, reducing hospitalizations and improving quality of life for patients."

[0201] Materials and Methods

[0202] Cell culture

[0203] NHBE cells

[0204] NHBE cells (Lonza, CC-2540) were cultured in complete BEGM (Lonza, CC-3171) with a supplement kit (Lonza, CC-4175) according to the manufacturer's protocol.

[0205] ALI culture

[0206] Transwells containing 12 mm or 6.5 mm 0.4-μm polyester membrane inserts (Corning, CLS3460 and CLS3470) were coated with CellAdhere type I collagen (Stemcell, 07001), diluted once in distilled H2O, and incubated at 37°C for 1 to 16 h, then washed with PBS.

[0207] Lung epithelia from healthy controls (bronchial [Lonza, CC-2540] or small airway [Epithelix, EP61SA]) or COPD patients (bronchial [Lonza, 195275] or small airway [Epithelix, EP66SA]) were grown in four T-175 flasks in Epix medium (Propagenix, 276-201) for bronchial cells or in small airway epithelial cell growth medium (PromoCell, C-21070) for small airway epithelial cells. Once confluent, cells were plated at passage 2 at 1×10 6 Cells at passage 2 were seeded in two T-75 flasks, grown to 80% confluence, then washed and detached using 6 ml of trypsin (Lonza, CC-5034). The cell suspension was centrifuged at 1,200 RPM for 5 minutes, and then the cells were plated at 8 × 10 5 10 cells / ml were resuspended in PneumaCult ALI medium (Stem Cell Technologies, 05001) for bronchial cells or PneumaCult ALI-S medium (Stem Cell Technologies, 05050) for small airway cells; 0.5 ml and 0.25 ml were distributed on each 12 mm and 6.5 mm insert, respectively, and 1 ml or 0.5 ml of ALI medium was added to the space below the corresponding insert. The cells were maintained in ALI medium until tight junctions were formed. The medium was then removed from the apical side and the cells were differentiated for 3 weeks, with the medium replaced at the base every 2 to 3 days.

[0208] Fully differentiated healthy cultures were left untreated or treated with IL-33 ox (30 ng / ml), unlabeled IL-33 C>S(30 ng / ml) or EGF (30 ng / ml). Differentiated COPD cultures were left untreated or treated with 1 μg / ml torezimab, 1 μg / ml NIP228 (IgG1 isotype control), 10 μg / ml mNIP228, 10 μg / ml anti-ST2, 1 μg / ml anti-RAGE (4F4), 1 μg / ml anti-EGFR (Millipore, clone LA1), or RAGE-FC (R&D Systems). For healthy and COPD ALI cultures, treatments were provided at the base of the culture medium for 7 days. The culture medium was changed every 2 to 3 days. The antibodies used in this study are listed in Supplementary Table 5. Torezimab blocks IL-33 red Interacts with ST2L to directly inhibit IL-33 red / ST2L signaling, and it indirectly inhibits IL-33 by preventing the formation of oxidized IL-33 ox - RAGE / EGFR signaling (ESC manuscript in preparation).

[0209] Recombinant protein production

[0210] Cloning and expression of IL-33

[0211] The mature component encoding wild-type (WT) human IL-33 (aa 112 to 270), UniProt accession number 095760 (IL-33 red ) and an oxidation-resistant variant in which all four cysteine ​​residues were mutated to serine (IL-33 C>S ) cDNA molecules and cloned them into pJexpress 411 (DNA 2.0). WT IL-33 was considered to be in its reduced form (IL-33) in 2× DPBS stock buffer before addition to the culture medium. red Both sequences were modified to contain 10×His, Avitag, and Factor Xa protease cleavage site at the N-terminus (MHHHHHHHHHHAAGLNDIFEAQKIEWHEAAIEGR (SEQ ID NO: 12)). IL-33 was produced by transforming Escherichia coli BL21 (DE3) cells. red (N-terminally tagged with His10 / Avitag; WT, SEQ ID NO: 13) and IL-33 C>S(N-terminally labeled His10 / Avitag; WT, SEQ ID NO: 14), cultured at 37°C for 18 hours in autoinduction medium (Overnight Express Auto-Induction System 1, Merck Millipore, 71300-4), collected by centrifugation and stored at -20°C. The cells were resuspended in 2×DPBS containing a completely EDTA-free protease inhibitor cocktail tablet (Roche Group, 11697498001) and 50U / ml Benzonase nuclease (Merck Millipore, 70746-3) and lysed by sonication. The cell lysate was centrifuged at 50,000×g for 30 minutes at 4°C. IL-33 protein was purified from the supernatant by immobilized metal affinity chromatography and further purified by size exclusion chromatography (SEC) using a HiLoad 26 / 600 Superdex 75pg column (GE Healthcare Group, 28989334). The peak fractions were analyzed by SDS PAGE. The fractions containing pure IL-33 were pooled and their concentrations were determined by measuring the absorbance at 280 nm. The final samples were analyzed by SDS-PAGE. red or IL-33 C>S , N-terminally labeled His10 / Avitag IL-33 was incubated with 10 units of Factor Xa (GE Healthcare, 27084901) per mg of protein in 2× DPBS at room temperature for 1 hour. Unlabeled IL-33 was purified using SEC on a HiLoad 16 / 600 Superdex 75pg column (GE Healthcare, 28989333) at a flow rate of 1 ml / min.

[0212] IL-33 ox Generation and purification of

[0213] IL-33 red Oxidation was performed by diluting in 60% IMDM (without phenol red) and 40% DPBS to a final concentration of 0.5 mg / ml. IL-33 was oxidized by incubation with factor Xa (NEB, P8010L) at 22°C at 1 μg / 50 μg ox The final concentration of IL-33 was incubated for 120 minutes. ox To deplete any remaining IL-33 in the sample red Soluble human ST2 fused to human IgG1 Fc-His6 was incubated with the sample at 22°C for 30 minutes. The sample was concentrated and loaded onto a HiLoad 26 / 600 Superdex 75pg column (GE Healthcare, 28989334) at a flow rate of 2 ml / min. Each column containing pure IL-33 was tested. oxThe ability of the fractions to activate EGFR (homogeneous time-resolved fluorescence [HTRF] assay in A549 cells and NHBE cells) was measured. The active fractions were combined and concentrated, and the final concentration of the sample was determined at 280 nm using UV absorption spectroscopy. The final product quality was evaluated by SDS-PAGE, high-efficiency SEC, and reversed-phase HPLC.

[0214] qPCR

[0215] After 7 days of treatment, 4-week-old healthy cultures or COPD ALI cultures on 6.5 mm inserts were lysed for RNA analysis. Each ALI apical surface was incubated with 200 μl PBS at 37°C for 30 minutes. RNA was extracted using the Direct-zolRNA Miniprep kit (Zymo Research, R2050). For deep cultures (A549 cells, HUVEC and NHBE cells), the RNeasy mini kit (Qiagen, 74104) was used. cDNA was synthesized using a high-capacity RNA-to-cDNA kit (Thermo Fisher Scientific, 4388950).

[0216] For RT-qPCR, 4 μl cDNA, 5 μl TaqMan Fast Advanced Master Mix (Thermo Fisher, 4444557), 0.5 μl MUC5AC FAM probe (Thermo Fisher, Hs01365616_m1) or MUC2 (Thermo Fisher, Hs00894041_g1) or CST1 (Thermo Fisher, Hs00606961_m1) or ST2 long (Thermo Fisher, Hs00249389_m1) or ST2 short (Thermo Fisher, Hs01073297_m1), and 0.5 μl GAPDH VIC probe (Thermo Fisher, Hs02786624_g1) were added to MicroAmp EnduraPlate (Thermo Fisher, 4483273). The plates were sealed and centrifuged briefly before analysis using the QuantStudio 7Flex Real-Time PCR System (Thermo Fisher Scientific). ΔΔCT was calculated by normalizing the data to untreated controls.

[0217] Bulk RNA Sequencing

[0218] RNA extracted from ALI cultures was processed externally by Source BioScience (Cambridge, UK). Libraries were prepared using the Illumina RNA Strand Kit. Sequencing was performed on an Illumina NovaSeq 6000 system to generate 30M150 base pair double-end reads. RNA libraries were prepared according to the following protocol: NEBNext UltraII Directional RNA Sample Preparation Protocol for Illumina Paired-End Multiplexed Sequencing [NEBNext Ultra II Directional RNA Sample Preparation Protocol for Illumina Paired-End Multiplexed Sequencing].

[0219] Using STAR 49 MultiQC alignment with GRCh38 ensembl (v100) human genome 48 Check the quality of the sequencing library. Use NGmerge 50 Adapter trimming was performed and Salmon was used 51 GRCh38 ensembl (v100) was used as a reference for gene expression quantification. 52 and Bioconda software management tool 53 to organize bioinformatics workflows. 55 DESeq2 with fold shrinkage 54 The package was used to perform differential expression analysis in R. Multiple correction of P values ​​was performed using the Benjamini-Hochberg method. 56 . Spotfire (TIBCO) data analysis software was used to create volcano plots showing fold changes and q values. Gene set variation analysis (GSVA) ​​was used 57 To calculate the gene expression of COPD patients in the public dataset GSE37147 44 、GSE11784 46 and GSE47460 45 Gene set enrichment scores by sample for the features generated in . Calculations were performed using the GSVA package in R. Patient groups were compared based on disease and smoking status for gene sets GSE37147 and GSE11784, and COPD severity by GOLD stage for GSE47460. Significance was calculated using one-way ANOVA followed by post hoc pairwise comparisons with Tukey's honestly significant difference test performed in Prism 9 (GraphPad).

[0220] Single-cell RNA sequencing

[0221] As described in the FACS analysis section, single cell suspensions of ALI cultures were generated, washed twice with PBS / 0.04% BSA and resuspended at 900 cells / μl. Cells were mixed with reagents from the ChromiumNextGEM SingleCell 3'GEM Kit v3.1 (10xGenomics, 1000123) according to the manufacturer's instructions. Both the sample mixture and capture beads from the ChromiumNextGEMSingle Cell 3'Gel Bead Kit v3.1 (10x Genomics, 1000122) were loaded onto a microfluidic chip, the Chromium Next GEM Chip G (10xGenomics, 2000177), aiming to capture 8000 cells for each sample. The chip was run on the Chromium Single Cell Controller (10xGenomics, GCG-SR-1) for single-cell partitioning and barcoding, and cDNA was prepared using the Chromium Next GEM Single Cell 3'GEM Kit v3.1 (10xGenomics, 1000123). The data were aligned to the GRCh38-3.0.0 human reference genome using CellRanger v3.0.1 (10xGenomics). Seurat v3.2.3 in R v3.6.3 was used. 58 The package performs normalization and downstream analysis. The raw counts were normalized and scaled using the Seurat functions NormalizeData and ScaleData (default parameters). Uniform manifold approximation and projection (UMAP) dimensionality reduction was obtained by applying Seurat's RunUMAP function and considering the top 2,000 most variable genes, and the 25 first principal components (PCA) were obtained using Seurat's RunPCA function. For healthy donors (n=1), cell clustering was performed by applying Seurat's functions FindNeighbors and FindClusters. A resolution of 0.5 was applied because this subdivided the clusters containing goblet cell identity. Clusters that showed high proximity in the phylogenetic tree obtained using BuildClusterTree were merged. Cell cluster markers were obtained using Seurat's FindAllMarkers function (non-parametric Wilcoxon rank sum test) and used for cluster annotation. Clusters were sorted according to the highly expressed genes and known epithelial airway cell markers of each cluster (Supplementary Figure 1 and Supplementary Table 3) 17,20,59-61To manually annotate cell types. Healthy donors were used as references to project cell annotations onto COPD donors (n=3) using the TransferData function of Seurat. All differential gene expression analyses between treatments were performed using the nonparametric Wilcoxon rank sum test using the Seurat functions FindMarkers and FindAllMarkers. Genes considered differentially expressed showed a log-fold change cutoff of 0.5 and an adjusted P value for multiple testing (Bonferroni correction) below 0.001.

[0222] Statistical analysis

[0223] Statistical analyses were performed using R (v.4.0.2) or Prism9 (GraphPad), which were also used to generate figures. Unless otherwise stated, data are presented as mean with standard error of the mean, and one-way ANOVA was followed by Tukey's test for comparisons between more than two groups. For P values, a significance threshold of 0.05 was used. Box plots were generated using the following parameters: the horizontal black line of each box represents the median; the box extends from the 25th percentile to the 75th percentile of the value; the whiskers extend outside the box to a maximum of 1.5 × interquartile range (75th percentile - 25th percentile); for each box, the lowest point is the minimum value and the highest point is the maximum value. Unless otherwise stated, all experiments are represented by several biological replicates or independent experiments. The number of replicates for each experiment is shown in the figure legends. Quantitative Venn diagrams of mass spectrometry data were generated using the Bioinformatics & Evolutionary Genomics web tool 62 All Western blots, co-immunoprecipitation experiments, FACS analysis, ELISA, and RT-qPCR were independently replicated at least twice with similar results. No statistical methods were used to predetermine sample size.

[0224] Other references

[0225] 17Jackson, ND et al. Single-cell and population transcriptomics reveal pan-epithelial remodeling in type 2-high asthma. Cell Rep. 32, 107872 (2020).

[0226] 20Ruiz García,S.et al.Novel dynamics of human mucociliarydifferentiation revealed by single-cell RNA sequencing ofnasal epithelialcultures.Development 146,dev177428(2019).

[0227] 44 Steiling,K.et al.A dynamic bronchial airway geneexpressionsignature of chronic obstructive pulmonary disease and lung functionimpairment.Am.J.Respir.Crit.Care Med.187,933-942(2013).

[0228] 45 Tan,J.et al.Expression of RXFP1 is decreased inidiopathicpulmonary fibrosis.Implications for relaxin-basedtherapies.Am.J.Respir.Crit.Care Med.194,1392-1402(2016).

[0229] 46 Tilley,A.E.et al.Biologic phenotyping of the human smallairwayepithelial response to cigarette smoking.PLoS One 6,e22798(2011).

[0230] 48 Ewels,P.,Magnusson,M.,Lundin,S.&Kaller,M.MultiQC:summarizeanalysis results for multiple tools and samples in asinglereport.Bioinformatics 32,3047-3048(2016).

[0231] 49 Dobin,A.et al.STAR:ultrafast universal RNA-seqaligner.Bioinformatics 29,15-21(2013).

[0232] 50 Gaspar,J.M.NGmerge:merging paired-end reads via novelempirically-derived models of sequencing errors.BMC Bioinformatics 19,536(2018).

[0233] 51 Patro,R.,Duggal,G.,Love,M.I.,Irizarry,R.A.&Kingsford,C.Salmonprovides fast and bias-aware quantification of transcriptexpression.Nat.Methods 14,417-419(2017).

[0234] 52 Di Tommaso,P.et al.Nextflow enables reproduciblecomputationalworkflows.Nat.Biotechnol.35,316-319(2017).

[0235] 53 Gruning,B.et al.Bioconda:sustainable and comprehensivesoftwaredistribution forthe life sciences.Nat.Methods 15,475-476(2018).

[0236] 54 Love,M.I.,Huber,W.&Anders,S.Moderated estimation offold change anddispersion for RNA-seq data with DESeq2.Genome Biol.15,550(2014).

[0237] 55 Zhu,A.,Ibrahim,J.G.&Love,M.I.Heavy-tailed priordistributions forsequence count data:removing the noise and preservinglargedifferences.Bioinformatics 35,2084-2092(2019).

[0238] 56 Storey,J.D.&Tibshirani,R.Statistical significance forgenomewidestudies.Proc.Natl.Acad.Sci.USA 100,9440-9445(2003).

[0239] 57 Hanzelmann,S.,Castelo,R.&Guinney,J.GSVA:gene set variationanalysis for microarray and RNA-seq data.BMC Bioinformatics14,7(2013).

[0240] 58Stuart,T.et al.Comprehensive integration of single-cell data.Cell177,1888-1902.e1821(2019).

[0241] 59Deprez,M.et al.A single-cell atlas of the human healthyairways.Am.J.Respir.Crit.Care Med.202,1636-1645(2020).

[0242] 60Travaglini,K.J.et al.A molecular cell atlas ofthe human lung fromsingle-cell RNA sequencing.Nature 587,619-625(2020).

[0243] 61 Vieira Braga, F.A. et al. A cellular census of human lungs identifies novel cell states in health and in asthma. Nat. Med. 25, 1153 - 1163 (2019).

[0244] 62 Bioinformatics and evolutionary genomics. https: / / bioinformatics.psb.ugent.be / cgi-bin / liste / Venn / calculate_venn.htpl

[0245] Sequence

[0246]

[0247]

[0248]

Claims

1. An IL-33 antagonist for use in a method of treating a subject suffering from an IL-33-mediated respiratory disorder to reduce or prevent respiratory tract infection.

2. The IL-33 antagonist for use according to claim 1, wherein the IL-33-mediated respiratory disease is chronic obstructive pulmonary disease (COPD).

3. An IL-33 antagonist for use according to any preceding claim, wherein the infection is a respiratory viral infection or a respiratory bacterial infection.

4. The IL-33 antagonist for use according to claim 3, wherein the infection is a respiratory viral infection caused by influenza virus (e.g., influenza A virus, influenza B virus), respiratory syncytial virus (RSV), adenovirus, metapneumovirus, cytomegalovirus, parainfluenza virus (e.g., hPIV-1, hPIV-2, hPIV-3, hPIV-4), rhinovirus, adenovirus, coxsackievirus, echovirus, coronavirus, herpes simplex virus, SARS coronavirus or smallpox.

5. The IL-33 antagonist for use according to any one of claims 1 to 3, wherein the infection is a respiratory bacterial infection caused by Chlamydia pneumoniae or Mycoplasma pneumoniae.

6. An IL-33 antagonist for use according to any preceding claim, wherein the IL-33 antagonist inhibits IL-33ox activity, thereby increasing club cell activity in the airway epithelium.

7. An IL-33 antagonist for use according to any preceding claim, wherein the IL-33 antagonist inhibits IL-33ox activity thereby increasing the total club cell area in the airway epithelium.

8. An IL-33 antagonist for use according to any preceding claim, wherein the IL-33 antagonist inhibits IL-33ox activity, thereby increasing the mRNA expression level of one or more markers selected from the group consisting of SCGB1BA1, BPIFA1, SCGB3A1, WFDC2, MSMB, LTF, SLPI, C3, HLA-DRA, CXCL1, CD74, CXCL17, MDK, TGM2, HLA-DRB1, CXCL8, CXCL2, HLA-DRB5, CX3CL1 and HLA-DPA1 in the airway epithelium.

9. An IL-33 antagonist for use according to any preceding claim, wherein the IL-33 antagonist inhibits IL-33ox activity, thereby increasing the mRNA expression level of one or more markers selected from the group consisting of SCGB1BA1, BPIFA1, SCGB3A1, WFDC2, MSMB and LTF in the airway epithelium.

10. The IL-33 antagonist for use according to claim 9, wherein the one or more markers are selected from SCGB1BA1 and BPIFA1.

11. An IL-33 antagonist for use according to any preceding claim, wherein the IL-33 antagonist inhibits IL-33ox activity, thereby increasing the protein expression level of one or more markers selected from the following in the airway epithelium: CCSP, SCGB3A1, WFDC2, β-microspermogen, lactoferrin, SPLUNC1, secretory leukocyte protease inhibitor (SLPI), complement C3, HLA-DR α chain, CXC motif chemokine ligand 1 (CXCL1), cluster of differentiation 74 (CD74), CXC motif chemokine 17 (CXCL17), midkine (MDK), protein-glutamate amine gamma-glutamyltransferase 2 (TGM2), HLA class II histocompatibility antigen, DRB1 β chain (HLA-DRB1), chemokine (CXC motif) ligand 8 (CXCL8), chemokine (CXC motif) ligand 2 (CXCL2), HLA Class II histocompatibility antigens, DRB5β chain (HLA-DRB5), chemokine (C-X3-C motif) ligand 1 (CX3CL1) and class II major histocompatibility complex, DPα1 (HLA-DPA1).

12. An IL-33 antagonist for use according to any preceding claim, wherein the IL-33 antagonist inhibits IL-33ox activity, thereby increasing the protein expression level of one or more markers selected from the group consisting of CCSP, SCGB3A1, WFDC2, β-microspermogenin, lactotransferrin and SPLUNC1 in the airway epithelium.

13. The IL-33 antagonist for use according to claim 12, wherein the one or more markers are selected from CCSP and SPLUNC1.

14. An IL-33 antagonist for use according to any one of claims 6 to 13, wherein the airway epithelium comprises lower airway epithelium.

15. The IL-33 antagonist for use according to claim 14, wherein the lower airway epithelium comprises cuboidal epithelium.

16. The IL-33 antagonist for use according to claim 14, wherein the lower airway epithelium comprises squamous epithelium.

17. An IL-33 antagonist for use according to claims 6 to 13, wherein the airway epithelium comprises upper airway epithelium.

18. The IL-33 antagonist for use according to claim 17, wherein the upper airway epithelium comprises ciliated pseudostratified columnar epithelium.

19. The IL-33 antagonist for use according to any one of claims 8 to 18, wherein the mRNA expression level is measured by qRT-PCR.

20. The IL-33 antagonist for use according to claims 11 to 18, wherein the protein expression level is measured by enzyme-linked immunosorbent assay (ELISA), immunohistochemistry (IHC), immunofluorescence, flow cytometry or Western blotting.

21. An IL-33 antagonist for use according to any preceding claim, wherein the mRNA expression level or protein expression level is measured in a biological sample obtained from the subject.

22. The IL-33 antagonist for use according to claim 21, wherein the biological sample is selected from respiratory epithelial biopsy, bronchial brushings, bronchoalveolar fluid (BALF), sputum, serum, plasma or nasal mucosal lining fluid.

23. An IL-33 antagonist for use according to any preceding claim, wherein the IL-33 antagonist inhibits IL-33ox activity, thereby increasing club cell defence function in the airway epithelium.

24. The IL-33 antagonist for use according to claim 23, wherein increasing the club cell defense function in the airway epithelium comprises increasing the activity of one or more proteins selected from the group consisting of CCSP, SCGB3A1, WFDC2, β-microspermogenin, lactoferrin, SPLUNC1, SLPI, C3, HLA-DRA, CXCL1, CD74, CXCL17, MDK, TGM2, HLA-DRB1, CXCL8, CXCL2, HLA-DRB5, CX3CL1, and HLA-DPA1.

25. The IL-33 antagonist for use according to claim 24, wherein increasing the club cell defense function in the airway epithelium comprises increasing the activity of CCSP and / or SPLUNC1.

26. An IL-33 antagonist for use according to any one of claims 2 to 25, wherein the method reduces the annualized exacerbation rate in the subject.

27. An IL-33 antagonist for use according to any one of claims 2 to 26, wherein the method reduces the frequency of acute exacerbations of COPD (AECOPD) in the subject.

28. An IL-33 antagonist for use according to any preceding claim, wherein the IL-33 antagonist is an IL-33ox antagonist.

29. An IL-33 antagonist for use according to any preceding claim, which is an antibody or an antigen-binding fragment thereof.

30. The IL-33 antagonist for use according to claim 29, wherein the antibody or antigen-binding fragment specifically binds to a reduced form of IL-33 (IL-33red).

31. An IL-33 antagonist for use according to any preceding claim, which is an anti-IL-33 antibody comprising a VH domain comprising a HCDR1 having the sequence shown in SEQ ID NO: 1; a HCDR2 having the sequence shown in SEQ ID NO: 2; and a HCDR3 having the sequence shown in SEQ ID NO: 3; and a VL domain comprising a LCDR1 having the sequence shown in SEQ ID NO: 5; a LCDR2 having the sequence shown in SEQ ID NO: 6 and a LCDR3 having the sequence shown in SEQ ID NO:

7.

32. An IL-33 antagonist for use according to any preceding claim, which is an anti-IL-33 antibody comprising a VH domain having the sequence shown in SEQ ID NO:4 and a VL domain having the sequence shown in SEQ ID NO:

8.

33. An IL-33 antagonist for use according to any preceding claim, wherein reducing respiratory tract infection means reducing the frequency of respiratory tract infection in the subject.

34. The IL-33 antagonist for use according to claim 33, wherein the subject suffers from COPD, and the frequency of respiratory tract infections is reduced when the number of AECOPD in the subject over a period of time after treatment is statistically lower than the number of AECOPD over the same period of time before treatment.

35. An IL-33 antagonist for use according to claim 34, the period of time being greater than 6 months, optionally greater than 12 months, optionally between 12 and 24 months, such as 24 months.

36. A composition comprising an IL-33 antagonist for use in a method of treatment for preventing or reducing respiratory tract infection in a subject suffering from COPD.

37. A composition for use according to claim 36, wherein the respiratory tract infection is a respiratory viral infection.

38. A method for reducing or preventing respiratory tract infections in a subject with COPD, comprising administering to the subject a therapeutically effective amount of an IL-33 antagonist.

39. The method of claim 38, wherein the IL-33 antagonist inhibits the activity of oxIL-33.

40. The method of claim 38 or 39, wherein the respiratory tract infection is a respiratory viral infection.

41. The method of any one of claims 38 to 40, wherein the method reduces the annualized rate of acute exacerbations of COPD (AECOPD) in the subject.

42. An IL-33 antagonist for use in reducing AECOPD in a subject suffering from COPD, wherein the IL-33 antagonist inhibits IL-33ox activity, thereby reducing respiratory tract infection and AECOPD in the subject.

43. An IL-33 antagonist for use according to claim 42, wherein the IL-33 antagonist inhibits IL-33ox activity, thereby increasing the total club cell area in the epithelium.

44. An IL-33 antagonist for use according to any one of claims 42 or 43, wherein the IL-33 antagonist inhibits IL-33ox activity, thereby increasing the mRNA expression level of one or more markers selected from the group consisting of SCGB1BA1, BPIFA1, SCGB3A1, WFDC2, MSMB, LTF, SLPI, C3, HLA-DRA, CXCL1, CD74, CXCL17, MDK, TGM2, HLA-DRB1, CXCL8, CXCL2, HLA-DRB5, CX3CL1 and HLA-DPA1.

45. An IL-33 antagonist for use according to any one of claims 42 to 44, wherein the IL-33 antagonist inhibits IL-33ox activity, thereby increasing the protein expression level of one or more markers selected from the group consisting of CCSP, SCGB3A1, WFDC2, β-microspermogenin, lactoferrin, SPLUNC1, SLPI, C3, HLA-DRA, CXCL1, CD74, CXCL17, MDK, TGM2, HLA-DRB1, CXCL8, CXCL2, HLA-DRB5, CX3CL1 and HLA-DPA1.

46. ​​An IL-33 antagonist for use according to any one of claims 44 or 45, wherein the expression level is measured in a biological sample obtained from the subject.

47. The IL-33 antagonist for use according to claim 46, wherein the biological sample is selected from respiratory epithelial biopsy, bronchial brushings, bronchoalveolar fluid (BALF), sputum, serum, plasma or nasal mucosal lining fluid.

48. Use of an IL-33 antagonist in the preparation of a medicament for use in a method of preventing or reducing the treatment of a respiratory tract infection in a subject suffering from an IL-33 mediated respiratory disorder.

49. A method of preventing or reducing treatment of a respiratory tract infection in a subject suffering from an IL-33 mediated respiratory disorder, comprising administering to the subject a therapeutically effective amount of an IL-33 antagonist.

50. The use according to claim 48 or the method according to claim 49, wherein the method of treatment is as defined in any one of claims 1 to 35.

51. The use according to claim 48 or 50 or the method according to claim 49 or 50, wherein the IL-33 antagonist is as defined in any one of claims 28 to 32.